👪

Inheritance

1

Autosomal Dominant HP:0000006

Glut1DS is most commonly caused by a heterozygous SLC2A1 pathogenic variant inherited in an autosomal dominant manner. About 90% of individuals have the disorder as the result of a de novo SLC2A1 pathogenic variant; about 10% have a variant inherited from a parent, whose degree of impairment may be mild or nonexistent (possible parental somatic mosaicism). Rare biallelic (autosomal recessive) inheritance has also been reported.

Autosomal dominant inheritance

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"Glut1DS is most commonly caused by a heterozygous SLC2A1 pathogenic variant and inherited in an autosomal dominant manner. About 90% of individuals with Glut1DS have the disorder as the result of a de novo SLC2A1 pathogenic variant; about 10% of individuals have the disorder as the result of a..."

GeneReviews genetic counseling section directly documents autosomal dominant inheritance, predominantly de novo, with a minority of inherited cases.

◆

Subtypes

3

Classic (Severe, Infantile-Onset) GLUT1 Deficiency Syndrome

The most common and severe presentation, with onset in infancy to early childhood. Predominant clinical findings are paroxysmal eye-head movements, pharmacoresistant seizures of varying types, deceleration of head growth, and developmental delay, followed by complex movement disorders and intellectual disability ranging from mild to severe.

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"When first diagnosed in infancy to early childhood, the predominant clinical findings of Glut1DS are paroxysmal eye-head movements, pharmacoresistant seizures of varying types, deceleration of head growth, and developmental delay."

GeneReviews describes the classic infantile-onset presentation as the most common and severe form of Glut1DS.

GLUT1 Deficiency Syndrome 2 (DYT18 / Paroxysmal Exercise-Induced Dyskinesia)

A milder, later-onset (childhood) form dominated by paroxysmal dystonic attacks of the extremities triggered by prolonged physical exertion, with or without epilepsy or hemolytic anemia. Corresponds to OMIM PS612126 / MONDO childhood-onset GLUT1 deficiency syndrome 2 (DYT18).

Show evidence (1 reference)

PMID:21649651 SUPPORT Human Clinical

"This paper also shows phenotypical parallels between GLUT1DS and paroxysmal exertion-induced dyskinesia."

Directly documents the milder paroxysmal exertion-induced dyskinesia phenotype as part of the GLUT1DS spectrum.

Dystonia 9 (DYT9 / Episodic Choreoathetosis with Spasticity)

An autosomal dominant SLC2A1-related dystonia characterized by paroxysmal choreoathetosis and progressive spastic paraplegia, with episodes often precipitated by alcohol, fatigue, or emotional stress. Corresponds to OMIM 601042.

?

Discussions and Knowledge Gaps

3

Which cellular intermediate translates chronic cerebral glucose under-supply into the specific pattern of neuronal hyperexcitability and hypersynchrony seen in Glut1DS — failure of the astrocyte-neuron lactate shuttle, selective energy vulnerability of fast-spiking GABAergic interneurons, disturbed adenosine/thalamocortical signaling, or a combination?

KNOWLEDGE GAP OPEN gap_glut1_energy_deficit_to_hyperexcitability_intermediate

Attached to

pathophysiology#Cerebral Glucose Energy Deficit pathophysiology#Neuronal Hyperexcitability and Hypersynchrony

The causal edge from "Cerebral Glucose Energy Deficit" to "Neuronal Hyperexcitability and Hypersynchrony" is curated as INDIRECT_KNOWN_INTERMEDIATES, but the identity of that intermediate is not actually established. Glucose reaches the brain almost exclusively through GLUT1, yet why a global fuel shortfall produces the particular Glut1DS electroclinical signature (including 2.5-4 Hz generalized spike-wave and absence-like seizures) rather than diffuse depression is unresolved. Candidate mechanisms — astrocytic lactate-supply failure, preferential ATP starvation of parvalbumin interneurons whose high firing rates make them metabolically expensive, and adenosine-mediated network effects — carry different therapeutic implications, so resolving the intermediate would materially sharpen the mechanism model.

Proposed experiments

Cell-type-resolved metabolic-to-excitability mapping in Glut1 haploinsufficiency

cell-type-resolved metabolic and excitability mapping experiment

exp_glut1_celltype_metabolic_intermediate

In GLUT-1+/- mice and patient-derived iPSC neuron-astrocyte co-cultures, simultaneously measure astrocytic lactate output, interneuron-specific ATP/metabolic stress, and network excitability, then test whether interneuron-targeted metabolic rescue (or lactate supplementation) normalizes hypersynchrony independently of restoring bulk neuronal glucose.

Perturbations

Interneuron-selective metabolic rescue

pathophysiology#Cerebral Glucose Energy Deficit

Selectively supply alternative fuel (lactate/ketone) or restore GLUT1 in astrocytes vs interneurons vs principal neurons to identify the rate-limiting compartment.

Readouts

Network hyperexcitability

pathophysiology#Neuronal Hyperexcitability and Hypersynchrony

multielectrode array recording electroencephalography

Direction: POSITIVE

Controls

Wild-type co-cultures

GLUT1-normal neuron-astrocyte co-cultures under matched glucose conditions.

Decision criterion

An intermediate is supported if rescuing a single cell compartment (e.g., astrocytic lactate supply or interneuron energetics) normalizes network excitability while leaving bulk neuronal glucose uptake unchanged.

Would support

pathophysiology#Neuronal Hyperexcitability and Hypersynchrony

Show evidence (2 references)

PMID:20301603 SUPPORT Human Clinical

"Glucose, the essential metabolic fuel for the brain, is transported into the brain exclusively by the protein glucose transporter type 1 (Glut1) across the endothelial cells forming the blood-brain barrier (BBB)."

Establishes the exclusive GLUT1 route for cerebral glucose, framing why the deficit is global; the open question is which cell type first converts that global shortfall into focal-onset hyperexcitability.

PMID:16497725 SUPPORT Model Organism

"GLUT-1+/- mice have epileptiform discharges on electroencephalography (EEG), impaired motor activity, incoordination, hypoglycorrhachia, microencephaly, decreased brain glucose uptake as measured by positron emission tomography (PET) scan and decreased brain Glut-1 expression by western blot (66%)."

Provides a tractable in vivo system in which the epileptiform phenotype is reproduced, i.e., a model where the missing cellular intermediate could be dissected with cell-type-specific readouts.

Why does ketone-based fuel substitution robustly control seizures in Glut1DS yet only partially rescue the movement disorder and cognitive impairment — is the residual deficit a missed developmental window, regional or functional under-supply of ketone-derived fuel, or a non-fuel role of glucose that ketones cannot replace?

KNOWLEDGE GAP OPEN gap_glut1_ketogenic_seizure_vs_neurodevelopment_dissociation

Attached to

pathophysiology#Cerebral Glucose Energy Deficit pathophysiology#Impaired Neurodevelopment and Movement Disorder pathophysiology#Recurrent Pharmacoresistant Seizures

Ketogenic diet therapy is the mainstay treatment and supplies ketone bodies as an alternative cerebral fuel that bypasses the GLUT1 transport defect. In practice it controls seizures far more completely than it reverses the paroxysmal movement disorder, ataxia/dystonia, or cognitive outcome, and outcomes are consistently better with earlier treatment. Whether the residual, seizure-independent morbidity reflects irreversible injury incurred before diagnosis (a developmental-window effect), inadequate ketone delivery to specific circuits, or a role of glucose beyond bulk fuel (e.g., biosynthetic/pentose-phosphate demands) is unresolved — and it determines whether earlier or supplemental (e.g., anaplerotic) therapy could close the gap.

Proposed experiments

Treatment-timing dissociation of seizure vs neurodevelopmental endpoints

treatment-timing endpoint dissociation experiment

exp_glut1_treatment_timing_endpoint_dissociation

In GLUT-1+/- mice, initiate ketogenic therapy or GLUT1 repletion across a graded set of ages and measure seizure/EEG control separately from motor coordination, brain growth, and cognitive-behavioral endpoints, testing whether the neurodevelopmental endpoints have an earlier closing window than the seizure endpoint.

Perturbations

Age-graded ketogenic/repletion therapy

pathophysiology#Cerebral Glucose Energy Deficit

Start fuel substitution or GLUT1 repletion at several developmental ages.

Readouts

Seizure control

pathophysiology#Recurrent Pharmacoresistant Seizures

electroencephalography

Direction: NEGATIVE

Motor and neurodevelopmental outcome

pathophysiology#Impaired Neurodevelopment and Movement Disorder

behavioral assay

Direction: POSITIVE

Controls

Untreated mutants and wild-type

Matched untreated GLUT-1+/- and wild-type animals.

Decision criterion

A developmental-window explanation is supported if neurodevelopmental endpoints lose responsiveness at an earlier treatment age than seizure control does; a fuel-limitation explanation is supported if both endpoints respond equally whenever adequate alternative fuel is supplied.

Would support

pathophysiology#Impaired Neurodevelopment and Movement Disorder

Show evidence (3 references)

PMID:20301603 SUPPORT Human Clinical

"Targeted therapy: Age-specific KDTs primarily provide a supplemental fuel, namely, ketone bodies, for brain energy metabolism."

Establishes that ketogenic therapy acts by fuel substitution, framing the question of why fuel substitution rescues seizures more completely than neurodevelopmental outcomes.

PMID:20301603 SUPPORT Human Clinical

"Typically, the earlier the treatment the better the long-term clinical outcome."

Documents the developmental-window dependence of outcome, one of the competing explanations for the residual neurodevelopmental deficit.

PMID:28106060 SUPPORT Model Organism

"Restoring the protein to 2-week old mutants, in which certain disease characteristics are readily apparent, is less effective in shaping normal brain microvasculature."

Model-organism evidence that later restoration incompletely reverses structural brain defects, supporting a developmental-window contribution to residual, seizure-independent morbidity.

Does the GLUT-1+/- mouse faithfully model the full human Glut1DS phenotype — in particular the paroxysmal features (paroxysmal eye-head movements, exercise-induced dyskinesia) and the spectrum extending to early-onset absence epilepsy and movement-disorder-predominant presentations — or does it capture mainly the core seizure/hypoglycorrhachia/microcephaly triad?

HUMAN MODEL MISMATCH OPEN gap_glut1_mouse_model_paroxysmal_phenotype_fidelity

Attached to

pathophysiology#Neuronal Hyperexcitability and Hypersynchrony pathophysiology#Impaired Neurodevelopment and Movement Disorder

The GLUT-1+/- mouse reproduces epileptiform EEG, motor impairment, hypoglycorrhachia and microencephaly and is described as mimicking the classical human presentation, making it the workhorse model for Glut1DS. But the human disorder is defined as much by paroxysmal, activity- and fasting-triggered phenomena and by a wide phenotypic spectrum (paroxysmal exercise-induced dyskinesia, early-onset absence epilepsy, isolated movement disorder) that depend on human-specific behavioral repertoire and developmental glucose-demand timing. Whether these paroxysmal and spectrum-defining features are recapitulated — and thus whether the model can validate therapies aimed at them — is the open translational question, distinct from a claim that evidence is simply absent.

Proposed experiments

Provocation phenotyping of paroxysmal features in Glut1 models

provocation phenotyping experiment

exp_glut1_paroxysmal_phenotype_provocation

Deep-phenotype GLUT-1+/- mice and patient-derived neuronal/BBB models under physiological provocations (fasting, exertion, post-prandial state) to test for movement-triggered dyskinesia-like events and absence-like spike-wave, comparing directly against the documented human paroxysmal spectrum.

Readouts

Paroxysmal movement and absence-like events

pathophysiology#Impaired Neurodevelopment and Movement Disorder

behavioral assay electroencephalography

Direction: POSITIVE

Controls

Wild-type littermates under identical provocation

Matched wild-type animals exposed to the same fasting/exertion protocols.

Decision criterion

Human fidelity for the paroxysmal spectrum is supported if physiological provocations reproducibly elicit movement-triggered dyskinesia-like events and absence-like discharges in mutants but not controls; absence of such events flags a genuine human/model mismatch for these features.

Would support

pathophysiology#Impaired Neurodevelopment and Movement Disorder

Show evidence (1 reference)

PMID:16497725 SUPPORT Model Organism

"The GLUT-1+/- murine phenotype mimics the classical human presentation of Glut-1 DS."

Documents fidelity to the classical core phenotype; the open question is whether the paroxysmal and spectrum-defining human features are also captured.

⚙

Pathophysiology

6

SLC2A1 Loss-of-Function Variant

Heterozygous (rarely biallelic) pathogenic variants in SLC2A1 reduce the amount or function of the GLUT1 facilitative glucose transporter protein, typically through haploinsufficiency.

SLC2A1 hgnc:11005

Downstream

Reduced GLUT1 Transporter Function at the Blood-Brain Barrier Loss-of-function SLC2A1 variants reduce the density or activity of GLUT1 transporters expressed on brain microvascular endothelial cells.

Show evidence (2 references)

PMID:20301603 SUPPORT Human Clinical

"The diagnosis of Glut1DS is established in a proband with suggestive clinical findings, hypoglycorrhachia documented by lumbar puncture, and a (usually) heterozygous pathogenic variant in SLC2A1 identified by molecular genetic testing."

GeneReviews establishes heterozygous SLC2A1 pathogenic variants as the molecular cause of Glut1DS.

PMID:12029447 SUPPORT Human Clinical

"Several heterozygous mutations resulting in GLUT1 haploinsufficiency have been identified."

Review paper documents the haploinsufficiency mechanism underlying heterozygous SLC2A1 mutations.

Reduced GLUT1 Transporter Function at the Blood-Brain Barrier

GLUT1 is the transporter responsible for facilitated glucose diffusion across the endothelial cells that form the blood-brain barrier, as well as glucose uptake into erythrocytes. Reduced GLUT1 activity impairs the rate at which glucose can be delivered from blood to brain, independent of blood glucose concentration.

canonical glut1 energy deficit

Brain Microvascular Endothelial Cell CL:2000044 Erythrocyte CL:0000232

D-glucose transmembrane transport GO:1904659 ↓ DECREASED

D-glucose transmembrane transporter activity GO:0055056 ↓ DECREASED

Downstream

Cerebral Glucose Energy Deficit Insufficient transendothelial glucose flux starves brain tissue of its principal metabolic substrate, independent of normal peripheral blood glucose levels.

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"Glucose, the essential metabolic fuel for the brain, is transported into the brain exclusively by the protein glucose transporter type 1 (Glut1) across the endothelial cells forming the blood-brain barrier (BBB). Glut1DS results from the inability of Glut1 to transfer sufficient glucose across..."

GeneReviews defines the core defect as insufficient GLUT1-mediated glucose transfer across the blood-brain barrier.

Cerebral Glucose Energy Deficit

Chronic under-supply of glucose to neurons and glia produces a state of cerebral energy insufficiency during the period of childhood brain development when glucose demand is highest, driving neuronal hyperexcitability, impaired neurodevelopment, and deceleration of brain (and hence head) growth.

canonical glut1 energy deficit

Neuron CL:0000540

Generation of Precursor Metabolites and Energy GO:0006091 ↓ DECREASED

Downstream

Neuronal Hyperexcitability and Hypersynchrony Energy-deficient neurons and cortical circuits become hyperexcitable and hypersynchronous, generating the pharmacoresistant seizures characteristic of Glut1DS.

Impaired Neurodevelopment and Movement Disorder Sustained cerebral energy insufficiency during critical developmental windows impairs neurodevelopment and produces a complex movement disorder combining ataxia, dystonia, and spasticity, together with deceleration of head growth (acquired/progressive microcephaly).

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"The needs of the brain for glucose increase rapidly after birth, peaking in early childhood, remaining high until about age 10 years, then gradually decreasing throughout adolescence and plateauing in early adulthood."

GeneReviews explains why the cerebral energy deficit is most severe in infancy/early childhood when brain glucose demand peaks, framing the developmental basis of the classic phenotype.

Neuronal Hyperexcitability and Hypersynchrony

Cortical and subcortical neuronal networks deprived of adequate glucose fuel become hyperexcitable, producing hypersynchronous discharges that manifest as pharmacoresistant seizures of varying semiology. This node conforms to the shared epilepsy excitation-inhibition-imbalance final common pathway, substituting a metabolic (energy-deficit) upstream driver rather than a primary ion-channel lesion.

Neuron CL:0000540

Downstream

Recurrent Pharmacoresistant Seizures Hyperexcitable, hypersynchronous cortical networks manifest clinically as recurrent seizures.

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"the predominant clinical findings of Glut1DS are paroxysmal eye-head movements, pharmacoresistant seizures of varying types, deceleration of head growth, and developmental delay."

GeneReviews documents pharmacoresistant seizures as the predominant early clinical finding reflecting cortical hyperexcitability.

Impaired Neurodevelopment and Movement Disorder

Chronic cerebral energy deficit produces a complex, often paroxysmal movement disorder (ataxia, dystonia, spasticity), speech difficulty, and intellectual disability that can present alone or alongside epilepsy, reflecting the breadth of the GLUT1DS phenotypic spectrum.

Neuron CL:0000540

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"the predominant clinical findings of Glut1DS are usually complex paroxysmal movement disorders, spasticity, ataxia, dystonia, speech difficulty, and intellectual disability."

GeneReviews describes the later-onset movement-disorder-predominant clinical picture directly arising from the same energy-deficit mechanism.

Recurrent Pharmacoresistant Seizures

The clinical endpoint of cortical hyperexcitability is recurrent, typically pharmacoresistant, epileptic seizures of varying types beginning in infancy or early childhood.

Neuron CL:0000540

Show evidence (1 reference)

PMID:25487684 SUPPORT Human Clinical

"The initial symptom was convulsive seizures, which occurred in 15 cases, and was followed by abnormal eye movements in 7 cases and apneic or cyanotic attacks in 4 cases."

Nationwide Japanese survey documents convulsive seizures as the most frequent presenting symptom.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

9

Musculoskeletal 2

Spasticity FREQUENT HP:0001257

Show evidence (1 reference)

PMID:25487684 SUPPORT Human Clinical

"Neurological findings revealed that most patients had muscle hypotonia, cerebellar ataxia, dystonia, and spastic paralysis."

Nationwide cohort documents spastic paralysis as a common neurological finding.

Hypotonia FREQUENT HP:0001252

Show evidence (1 reference)

PMID:25487684 SUPPORT Human Clinical

"Neurological findings revealed that most patients had muscle hypotonia, cerebellar ataxia, dystonia, and spastic paralysis."

Nationwide cohort documents muscle hypotonia as a common neurological finding.

Nervous System 5

Pharmacoresistant Seizures VERY_FREQUENT HP:0001250

Temporal: RECURRENT

Show evidence (1 reference)

PMID:25487684 SUPPORT Human Clinical

"Thirty-two patients (97%) exhibited some type of epileptic seizure."

Nationwide cohort of 33 confirmed GLUT1DS patients documents seizures in 97% of individuals, directly supporting VERY_FREQUENT.

Global Developmental Delay VERY_FREQUENT HP:0001263

Show evidence (1 reference)

PMID:25487684 SUPPORT Human Clinical

"Mild to severe mental retardation was detected in all 33 cases."

Nationwide cohort documents developmental/cognitive impairment in all 33 confirmed cases.

Ataxia FREQUENT HP:0001251

Show evidence (1 reference)

PMID:25487684 SUPPORT Human Clinical

"Neurological findings revealed that most patients had muscle hypotonia, cerebellar ataxia, dystonia, and spastic paralysis."

Nationwide cohort documents cerebellar ataxia as a common neurological finding in most patients.

Dystonia FREQUENT HP:0001332

Show evidence (1 reference)

PMID:25487684 SUPPORT Human Clinical

"Neurological findings revealed that most patients had muscle hypotonia, cerebellar ataxia, dystonia, and spastic paralysis."

Nationwide cohort documents dystonia as a common neurological finding.

Speech Difficulty Dysarthria HP:0001260

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"the predominant clinical findings of Glut1DS are usually complex paroxysmal movement disorders, spasticity, ataxia, dystonia, speech difficulty, and intellectual disability."

GeneReviews lists speech difficulty among predominant clinical findings in the later-onset presentation.

Other 2

Progressive (Acquired) Microcephaly Progressive microcephaly HP:0000253

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"the predominant clinical findings of Glut1DS are paroxysmal eye-head movements, pharmacoresistant seizures of varying types, deceleration of head growth, and developmental delay."

GeneReviews lists deceleration of head growth as a predominant early clinical finding.

Paroxysmal Exercise/Exertion-Induced Dyskinesia OCCASIONAL Paroxysmal dyskinesia HP:0007166

Temporal: RECURRENT

Show evidence (1 reference)

PMID:25487684 SUPPORT Human Clinical

"Furthermore, paroxysmal episodes of ataxia, dystonia/dyskinesia, and motor paralysis were described in approximately 1/3 of all patients. The factors that frequently aggravated these events were hunger, exercise, fever, and fatigue, in that order."

Nationwide cohort quantifies paroxysmal dyskinetic episodes in about a third of patients and identifies exertion/hunger/fever/fatigue as triggers.

🧬

Genetic Associations

1

SLC2A1 (Causative)

Gene: SLC2A1 hgnc:11005 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:20301603 SUPPORT Human Clinical

"Glut1DS is most commonly caused by a heterozygous SLC2A1 pathogenic variant and inherited in an autosomal dominant manner. About 90% of individuals with Glut1DS have the disorder as the result of a de novo SLC2A1 pathogenic variant; about 10% of individuals have the disorder as the result of a..."

GeneReviews genetic counseling section quantifies the de novo versus inherited variant origin split.

PMID:25487684 SUPPORT Human Clinical

"Pathological mutations in the SLC2A1 gene were identified in 28 out of 32 cases (87.5%)."

Nationwide Japanese cohort documents the molecular diagnostic yield of SLC2A1 testing among clinically suspected patients.

💊

Medical Actions

4

Ketogenic Diet Therapy

Action: ketogenic diet intake Ontology label: Ketogenic Diet NCIT:C173168

Age-specific ketogenic diet therapies (KDTs) supply ketone bodies as an alternative fuel for brain energy metabolism, bypassing the GLUT1 transport defect. Earlier initiation, ideally in infancy, is associated with better seizure control and long-term neurologic outcome. Effective for both seizure control and the movement disorder.

Mechanism Target:

BYPASSES Cerebral Glucose Energy Deficit

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"Targeted therapy: Age-specific KDTs primarily provide a supplemental fuel, namely, ketone bodies, for brain energy metabolism."

GeneReviews describes the ketogenic diet mechanism of action as supplying an alternative cerebral fuel that bypasses the GLUT1 transport defect.

Show evidence (2 references)

PMID:36303089 SUPPORT Human Clinical

"All patients were seizure-free within a month of receiving the diet therapy. All patients were followed up for six months, three were followed up for 12 months after the treatment, and there was no recurrence of epilepsy during this period."

Retrospective single-center cohort of SLC2A1-mutation patients demonstrates rapid and durable seizure control with ketogenic diet therapy.

PMID:20301603 SUPPORT Human Clinical

"Typically, the earlier the treatment the better the long-term clinical outcome."

GeneReviews documents that earlier ketogenic diet initiation yields better long-term neurologic outcome.

Triheptanoin

Action: Pharmacotherapy NCIT:C15986

Agent: Triheptanoin

Triheptanoin is an anaplerotic odd-chain (C7) medium-chain triglyceride that provides Krebs-cycle substrates and an alternative brain fuel independent of GLUT1. An open-label study reported marked reduction of non-epileptic paroxysmal manifestations and normalized brain bioenergetics, but a subsequent randomized placebo-controlled trial did not show a significant reduction in seizure frequency in patients not on a ketogenic diet, leaving its efficacy for the epilepsy phenotype unproven.

Mechanism Target:

BYPASSES Cerebral Glucose Energy Deficit

Show evidence (1 reference)

PMID:26536893 SUPPORT Human Clinical

"Treatment with triheptanoin resulted in a 90% clinical improvement in non-epileptic paroxysmal manifestations and a normalised brain bioenergetics profile in patients with GLUT1-DS."

Open-label study demonstrates triheptanoin supplies anaplerotic Krebs-cycle substrates that bypass the GLUT1 defect and normalize brain energy metabolism.

Show evidence (2 references)

PMID:26536893 SUPPORT Human Clinical

"Treatment with triheptanoin resulted in a 90% clinical improvement in non-epileptic paroxysmal manifestations and a normalised brain bioenergetics profile in patients with GLUT1-DS."

Open-label pilot study supports triheptanoin efficacy against the non-epileptic paroxysmal (movement-disorder) manifestations of GLUT1DS.

PMID:35441706 REFUTE Human Clinical

"Triheptanoin did not significantly reduce seizure frequency in patients with Glut1DS not on the ketogenic diet."

Randomized double-blind placebo-controlled trial qualifies the treatment claim by showing no significant seizure-frequency benefit for the epilepsy phenotype.

Anti-Seizure Medications to Avoid

In individuals on ketogenic diet therapy, valproic acid should be avoided because it increases the risk of a Reye-like illness and may also inhibit glucose transport; phenobarbital, acetazolamide, topiramate, and zonisamide may be relatively contraindicated as adjunctive treatment. This is a "circumstance to avoid" (GeneReviews Agents/Circumstances to Avoid section) rather than a recommended treatment; retained here as a treatment-adjacent drug-safety note.

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"Agents/circumstances to avoid: In individuals on KDTs: (1) avoidance of treatment of seizures with valproic acid, because it increases the risk of a Reye-like illness and may also inhibit glucose transport; (2) other anti-seizure medications (ASMs) including phenobarbital, acetazolamide,..."

GeneReviews Agents/Circumstances to Avoid section directly documents these drug-safety warnings for GLUT1DS patients on ketogenic diet therapy.

Multidisciplinary Supportive Care

Action: Supportive Care NCIT:C15747

Physical medicine and rehabilitation, physical therapy, occupational therapy, speech and language therapy, educational programs, and clinical genetics/genetic counseling, alongside routine neurology follow-up to monitor response to ketogenic diet therapy and identify new manifestations.

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"Supportive care: In addition to educational programs to address the individual's needs, multidisciplinary care by specialists in neurology familiar with KDTs, physical medicine and rehabilitation, physical therapy, occupational therapy, speech and therapy, and clinical genetics and genetic counseling."

GeneReviews management section documents the multidisciplinary supportive care regimen recommended alongside ketogenic diet therapy.

🔬

Biochemical Markers

1

Hypoglycorrhachia (Decreased)

Context: Low CSF glucose relative to blood glucose (CSF:blood glucose ratio typically below 0.4) in the setting of normoglycemia is the classic diagnostic biochemical signature of GLUT1DS, reflecting impaired GLUT1-mediated glucose transport across the blood-brain barrier.

Pathograph Readouts

Readout Of Reduced GLUT1 Transporter Function at the Blood-Brain Barrier Negative Diagnostic

A low CSF:blood glucose ratio reports reduced GLUT1-mediated glucose transport across the blood-brain barrier independent of systemic glucose levels.

Show evidence (1 reference)

PMID:21649651 SUPPORT Human Clinical

"the presence of normoglycaemia with a CSF/blood glucose ratio of less than 0.4."

Directly defines the diagnostic CSF:blood glucose ratio cutoff used clinically.

Show evidence (2 references)

PMID:25487684 SUPPORT Human Clinical

"The mean CSF/blood glucose ratio was 0.36 (0.28-0.48)."

Nationwide cohort of confirmed cases reports the empirical mean and range of the diagnostic CSF:blood glucose ratio.

PMID:12029447 SUPPORT Human Clinical

"The hallmark of the disease is a low glucose concentration in the CSF (hypoglycorrhachia) in the presence of normoglycaemia (CSF/blood glucose ratio <0.4)."

Review confirms hypoglycorrhachia with CSF:blood glucose ratio below 0.4 as the diagnostic hallmark.

🔬

Diagnosis

4

Lumbar Puncture with Paired CSF and Blood Glucose

Fasting lumbar puncture with simultaneous blood glucose measurement to demonstrate hypoglycorrhachia and calculate the CSF:blood glucose ratio, the key diagnostic biochemical test.

Show evidence (1 reference)

PMID:20301603 SUPPORT Human Clinical

"The diagnosis of Glut1DS is established in a proband with suggestive clinical findings, hypoglycorrhachia documented by lumbar puncture, and a (usually) heterozygous pathogenic variant in SLC2A1 identified by molecular genetic testing."

GeneReviews establishes lumbar puncture-documented hypoglycorrhachia as a core diagnostic criterion.

SLC2A1 Molecular Genetic Testing

Sequence analysis (and, if negative, gene-targeted deletion/duplication analysis) of SLC2A1 to identify the causative pathogenic variant.

Show evidence (1 reference)

PMID:25487684 SUPPORT Human Clinical

"Pathological mutations in the SLC2A1 gene were identified in 28 out of 32 cases (87.5%)."

Nationwide cohort demonstrates the diagnostic yield of SLC2A1 molecular testing in clinically suspected cases.

Erythrocyte GLUT1 Function Assay

The GLUT1 defect can be confirmed in erythrocytes by glucose uptake studies and GLUT1 immunoreactivity, providing a functional confirmatory test alongside molecular genetic testing.

Show evidence (1 reference)

PMID:12029447 SUPPORT Human Clinical

"The GLUT1 defect can be confirmed in erythrocytes by glucose uptake studies and GLUT1 immunoreactivity, and by molecular analysis of the GLUT1 gene."

Review documents erythrocyte glucose uptake and GLUT1 immunoreactivity as confirmatory functional diagnostic assays.

METAglut1 Erythrocyte Surface GLUT1 Blood Test

METAglut1 is a simple, noninvasive flow-cytometry blood test that quantifies GLUT1 protein on the surface of circulating erythrocytes, prospectively validated as a diagnostic test for GLUT1 deficiency syndrome and an alternative or complement to lumbar puncture. It can detect patients with SLC2A1 mosaicism and variants of unknown significance.

Show evidence (2 references)

PMID:37076312 SUPPORT Human Clinical

"METAglut1 was 80% sensitive and >99% specific for the diagnosis of Glut1DS."

Prospective multicenter validation reports the diagnostic sensitivity and specificity of the METAglut1 erythrocyte-surface GLUT1 blood test.

PMID:37076312 SUPPORT Human Clinical

"METAglut1 succeeded to identify patients with Glut1DS with SCL2A1 mosaicism and variants of unknown significance."

The blood test detects diagnostically challenging cases including SLC2A1 mosaicism and variants of unknown significance.

📊

Prevalence

1

Estimated (literature-based, likely underascertained)

Point Prevalence Not yet documented

No single precise population point-prevalence estimate was identified with a directly quotable abstract snippet during this curation pass; the Japan nationwide survey below instead gives a national case-ascertainment count that is informative but not a normalized rate, and is likely an underestimate due to underdiagnosis. This is recorded in notes rather than as a fabricated rate_per_100000 value.

Show evidence (1 reference)

PMID:25487684 SUPPORT Human Clinical

"A questionnaire to survey the number of genetically and clinically confirmed cases of GLUT-1DS was sent to 1018 board-certified pediatric neurologists, which resulted in 57 patients being reported."

Nationwide Japanese survey ascertained 57 genetically/clinically confirmed cases nationally, informative for rarity but not directly convertible to a per-100,000 rate without further population denominators.

{ }

Source YAML

click to show

name: GLUT1 Deficiency Syndrome
creation_date: "2026-07-06T00:00:00Z"
category: Mendelian
description: >-
  Glucose transporter type 1 (GLUT1) deficiency syndrome (Glut1DS) is a disorder
  of brain energy metabolism caused by heterozygous (rarely biallelic) pathogenic
  variants in SLC2A1, which encodes the GLUT1 facilitative glucose transporter
  responsible for transporting glucose across the endothelial cells of the
  blood-brain barrier and into erythrocytes. Reduced GLUT1 function starves the
  brain of its principal metabolic fuel, producing a cerebral energy deficit that
  manifests as an infantile-onset, often pharmacoresistant epileptic
  encephalopathy with acquired microcephaly, developmental delay, and a complex
  movement disorder (ataxia, dystonia, spasticity) in the classic severe form.
  Milder and later-onset presentations exist across a phenotypic spectrum,
  including paroxysmal exertion-induced dyskinesia (GLUT1 deficiency syndrome 2 /
  DYT18) and episodic choreoathetosis with spasticity (dystonia 9 / DYT9). The
  diagnostic hallmark is hypoglycorrhachia (low CSF glucose) with a low CSF:blood
  glucose ratio in the setting of normoglycemia. The ketogenic diet, which
  supplies ketone bodies as an alternative cerebral fuel bypassing the GLUT1
  transport defect, is first-line disease-specific therapy.
synonyms:
- Glut1DS
- GLUT1 DS
- De Vivo Disease
- Glucose Transporter Type 1 Deficiency Syndrome
- Encephalopathy due to GLUT1 Deficiency
disease_term:
  preferred_term: encephalopathy due to GLUT1 deficiency
  term:
    id: MONDO:0011724
    label: encephalopathy due to GLUT1 deficiency
references:
- reference: PMID:20301603
  title: "Glucose Transporter Type 1 Deficiency Syndrome."
  tags:
  - GeneReviews
  findings: []
parents:
- GLUT1 Deficiency Syndrome (Umbrella)
- Inborn Carbohydrate Metabolic Disorder
- Metabolic Epilepsy
has_subtypes:
- name: Classic GLUT1 Deficiency Syndrome
  display_name: Classic (Severe, Infantile-Onset) GLUT1 Deficiency Syndrome
  description: >-
    The most common and severe presentation, with onset in infancy to early
    childhood. Predominant clinical findings are paroxysmal eye-head movements,
    pharmacoresistant seizures of varying types, deceleration of head growth,
    and developmental delay, followed by complex movement disorders and
    intellectual disability ranging from mild to severe.
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "When first diagnosed in infancy to early childhood, the predominant clinical findings of Glut1DS are paroxysmal eye-head movements, pharmacoresistant seizures of varying types, deceleration of head growth, and developmental delay."
    explanation: GeneReviews describes the classic infantile-onset presentation as the most common and severe form of Glut1DS.
- name: GLUT1 DS with Paroxysmal Exertion-Induced Dyskinesia
  display_name: GLUT1 Deficiency Syndrome 2 (DYT18 / Paroxysmal Exercise-Induced Dyskinesia)
  description: >-
    A milder, later-onset (childhood) form dominated by paroxysmal dystonic
    attacks of the extremities triggered by prolonged physical exertion, with or
    without epilepsy or hemolytic anemia. Corresponds to OMIM PS612126 / MONDO
    childhood-onset GLUT1 deficiency syndrome 2 (DYT18).
  evidence:
  - reference: PMID:21649651
    reference_title: "Milder phenotypes of glucose transporter type 1 deficiency syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This paper also shows phenotypical parallels between GLUT1DS and paroxysmal exertion-induced dyskinesia."
    explanation: Directly documents the milder paroxysmal exertion-induced dyskinesia phenotype as part of the GLUT1DS spectrum.
- name: Dystonia 9
  display_name: Dystonia 9 (DYT9 / Episodic Choreoathetosis with Spasticity)
  description: >-
    An autosomal dominant SLC2A1-related dystonia characterized by paroxysmal
    choreoathetosis and progressive spastic paraplegia, with episodes often
    precipitated by alcohol, fatigue, or emotional stress. Corresponds to OMIM
    601042.
  review_notes: >-
    Mapped from MONDO:0010983 (dystonia 9, OMIM:601042), which the MONDO
    definition attributes to heterozygous SLC2A1 mutation. No independently
    quotable PubMed abstract snippet specific to this subtype's natural history
    was identified during curation beyond the MONDO/OMIM cross-reference itself;
    included here for completeness of the OMIM phenotypic series rather than
    with dedicated evidence.
inheritance:
- name: Autosomal Dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Glut1DS is most commonly caused by a heterozygous SLC2A1 pathogenic variant
    inherited in an autosomal dominant manner. About 90% of individuals have the
    disorder as the result of a de novo SLC2A1 pathogenic variant; about 10%
    have a variant inherited from a parent, whose degree of impairment may be
    mild or nonexistent (possible parental somatic mosaicism). Rare biallelic
    (autosomal recessive) inheritance has also been reported.
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Glut1DS is most commonly caused by a heterozygous SLC2A1 pathogenic variant and inherited in an autosomal dominant manner. About 90% of individuals with Glut1DS have the disorder as the result of a de novo SLC2A1 pathogenic variant; about 10% of individuals have the disorder as the result of a pathogenic variant inherited from a parent."
    explanation: GeneReviews genetic counseling section directly documents autosomal dominant inheritance, predominantly de novo, with a minority of inherited cases.
pathophysiology:
- name: SLC2A1 Loss-of-Function Variant
  description: >-
    Heterozygous (rarely biallelic) pathogenic variants in SLC2A1 reduce the
    amount or function of the GLUT1 facilitative glucose transporter protein,
    typically through haploinsufficiency.
  gene:
    preferred_term: SLC2A1
    term:
      id: hgnc:11005
      label: SLC2A1
  role: trigger
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of Glut1DS is established in a proband with suggestive clinical findings, hypoglycorrhachia documented by lumbar puncture, and a (usually) heterozygous pathogenic variant in SLC2A1 identified by molecular genetic testing."
    explanation: GeneReviews establishes heterozygous SLC2A1 pathogenic variants as the molecular cause of Glut1DS.
  - reference: PMID:12029447
    reference_title: "Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain-- a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Several heterozygous mutations resulting in GLUT1 haploinsufficiency have been identified."
    explanation: Review paper documents the haploinsufficiency mechanism underlying heterozygous SLC2A1 mutations.
  downstream:
  - target: Reduced GLUT1 Transporter Function at the Blood-Brain Barrier
    causal_link_type: DIRECT
    description: >-
      Loss-of-function SLC2A1 variants reduce the density or activity of GLUT1
      transporters expressed on brain microvascular endothelial cells.
    evidence:
    - reference: PMID:12029447
      reference_title: "Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain-- a review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "It is caused by a defect in glucose transport into brain, mediated by the facilitative glucose transporter GLUT1."
      explanation: Directly links the SLC2A1/GLUT1 defect to impaired glucose transport into the brain.
- name: Reduced GLUT1 Transporter Function at the Blood-Brain Barrier
  description: >-
    GLUT1 is the transporter responsible for facilitated glucose diffusion
    across the endothelial cells that form the blood-brain barrier, as well as
    glucose uptake into erythrocytes. Reduced GLUT1 activity impairs the rate at
    which glucose can be delivered from blood to brain, independent of blood
    glucose concentration.
  role: mediator
  cell_types:
  - preferred_term: Brain Microvascular Endothelial Cell
    term:
      id: CL:2000044
      label: brain microvascular endothelial cell
  - preferred_term: Erythrocyte
    term:
      id: CL:0000232
      label: erythrocyte
  molecular_functions:
  - preferred_term: D-glucose transmembrane transporter activity
    term:
      id: GO:0055056
      label: D-glucose transmembrane transporter activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: D-glucose transmembrane transport
    term:
      id: GO:1904659
      label: D-glucose transmembrane transport
    modifier: DECREASED
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Glucose, the essential metabolic fuel for the brain, is transported into the brain exclusively by the protein glucose transporter type 1 (Glut1) across the endothelial cells forming the blood-brain barrier (BBB). Glut1DS results from the inability of Glut1 to transfer sufficient glucose across the BBB to meet the glucose demands of the brain."
    explanation: GeneReviews defines the core defect as insufficient GLUT1-mediated glucose transfer across the blood-brain barrier.
  downstream:
  - target: Cerebral Glucose Energy Deficit
    causal_link_type: DIRECT
    description: >-
      Insufficient transendothelial glucose flux starves brain tissue of its
      principal metabolic substrate, independent of normal peripheral blood
      glucose levels.
    hypothesis_groups:
    - canonical_glut1_energy_deficit
    evidence:
    - reference: PMID:12029447
      reference_title: "Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain-- a review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome (MIM 138140) defines a prototype of a novel group of disorders resulting from impaired glucose transport across blood-tissue barriers."
      explanation: Review frames Glut1DS as the prototypic disorder of impaired glucose transport across blood-tissue barriers, i.e., a cerebral energy-deficit disease.
- name: Cerebral Glucose Energy Deficit
  description: >-
    Chronic under-supply of glucose to neurons and glia produces a state of
    cerebral energy insufficiency during the period of childhood brain
    development when glucose demand is highest, driving neuronal
    hyperexcitability, impaired neurodevelopment, and deceleration of brain (and
    hence head) growth.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Generation of Precursor Metabolites and Energy
    term:
      id: GO:0006091
      label: generation of precursor metabolites and energy
    modifier: DECREASED
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The needs of the brain for glucose increase rapidly after birth, peaking in early childhood, remaining high until about age 10 years, then gradually decreasing throughout adolescence and plateauing in early adulthood."
    explanation: GeneReviews explains why the cerebral energy deficit is most severe in infancy/early childhood when brain glucose demand peaks, framing the developmental basis of the classic phenotype.
  downstream:
  - target: Neuronal Hyperexcitability and Hypersynchrony
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Energy-deficient neurons and cortical circuits become hyperexcitable and
      hypersynchronous, generating the pharmacoresistant seizures characteristic
      of Glut1DS.
    hypothesis_groups:
    - canonical_glut1_energy_deficit
    evidence:
    - reference: PMID:25487684
      reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Thirty-two patients (97%) exhibited some type of epileptic seizure."
      explanation: Nationwide cohort documents near-universal seizure occurrence, the clinical readout of energy-deficit-driven cortical hyperexcitability.
  - target: Impaired Neurodevelopment and Movement Disorder
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Sustained cerebral energy insufficiency during critical developmental
      windows impairs neurodevelopment and produces a complex movement disorder
      combining ataxia, dystonia, and spasticity, together with deceleration of
      head growth (acquired/progressive microcephaly).
    evidence:
    - reference: PMID:20301603
      reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Subsequently children develop complex movement disorders and intellectual disability ranging from mild to severe."
      explanation: GeneReviews documents the progression from early seizures/developmental delay to complex movement disorder and intellectual disability.
- name: Neuronal Hyperexcitability and Hypersynchrony
  description: >-
    Cortical and subcortical neuronal networks deprived of adequate glucose fuel
    become hyperexcitable, producing hypersynchronous discharges that manifest
    as pharmacoresistant seizures of varying semiology. This node conforms to
    the shared epilepsy excitation-inhibition-imbalance final common pathway,
    substituting a metabolic (energy-deficit) upstream driver rather than a
    primary ion-channel lesion.
  role: central_effector
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the predominant clinical findings of Glut1DS are paroxysmal eye-head movements, pharmacoresistant seizures of varying types, deceleration of head growth, and developmental delay."
    explanation: GeneReviews documents pharmacoresistant seizures as the predominant early clinical finding reflecting cortical hyperexcitability.
  downstream:
  - target: Recurrent Pharmacoresistant Seizures
    causal_link_type: DIRECT
    description: Hyperexcitable, hypersynchronous cortical networks manifest clinically as recurrent seizures.
    evidence:
    - reference: PMID:25487684
      reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Thirty-two patients (97%) exhibited some type of epileptic seizure."
      explanation: Nationwide cohort documents near-universal seizure occurrence as the clinical manifestation of cortical hyperexcitability.
- name: Impaired Neurodevelopment and Movement Disorder
  description: >-
    Chronic cerebral energy deficit produces a complex, often paroxysmal
    movement disorder (ataxia, dystonia, spasticity), speech difficulty, and
    intellectual disability that can present alone or alongside epilepsy,
    reflecting the breadth of the GLUT1DS phenotypic spectrum.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the predominant clinical findings of Glut1DS are usually complex paroxysmal movement disorders, spasticity, ataxia, dystonia, speech difficulty, and intellectual disability."
    explanation: GeneReviews describes the later-onset movement-disorder-predominant clinical picture directly arising from the same energy-deficit mechanism.
- name: Recurrent Pharmacoresistant Seizures
  description: >-
    The clinical endpoint of cortical hyperexcitability is recurrent,
    typically pharmacoresistant, epileptic seizures of varying types beginning
    in infancy or early childhood.
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The initial symptom was convulsive seizures, which occurred in 15 cases, and was followed by abnormal eye movements in 7 cases and apneic or cyanotic attacks in 4 cases."
    explanation: Nationwide Japanese survey documents convulsive seizures as the most frequent presenting symptom.
phenotypes:
- name: Pharmacoresistant Seizures
  description: >-
    Seizures of varying types (often including absence, myoclonic, or
    generalized tonic-clonic seizures), typically beginning in infancy and
    frequently resistant to conventional anti-seizure medications, but
    responsive to ketogenic diet therapy.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
    temporality: RECURRENT
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-two patients (97%) exhibited some type of epileptic seizure."
    explanation: Nationwide cohort of 33 confirmed GLUT1DS patients documents seizures in 97% of individuals, directly supporting VERY_FREQUENT.
- name: Global Developmental Delay
  description: >-
    Delayed acquisition of motor and cognitive milestones, typically apparent
    from infancy, with mild-to-severe intellectual disability persisting into
    later childhood and adulthood.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mild to severe mental retardation was detected in all 33 cases."
    explanation: Nationwide cohort documents developmental/cognitive impairment in all 33 confirmed cases.
- name: Progressive (Acquired) Microcephaly
  description: >-
    Deceleration of head growth after a normal birth head circumference,
    reflecting impaired postnatal brain growth from the underlying cerebral
    energy deficit.
  phenotype_term:
    preferred_term: Progressive microcephaly
    term:
      id: HP:0000253
      label: Progressive microcephaly
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the predominant clinical findings of Glut1DS are paroxysmal eye-head movements, pharmacoresistant seizures of varying types, deceleration of head growth, and developmental delay."
    explanation: GeneReviews lists deceleration of head growth as a predominant early clinical finding.
- name: Ataxia
  description: >-
    Impaired coordination of voluntary movement, part of the complex movement
    disorder that emerges as GLUT1DS progresses.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  frequency: FREQUENT
  evidence:
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological findings revealed that most patients had muscle hypotonia, cerebellar ataxia, dystonia, and spastic paralysis."
    explanation: Nationwide cohort documents cerebellar ataxia as a common neurological finding in most patients.
- name: Dystonia
  description: >-
    Sustained or intermittent muscle contractions causing abnormal, often
    repetitive movements or postures; part of the complex movement disorder of
    GLUT1DS and the dominant feature of the paroxysmal-dyskinesia-predominant
    subtype.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  frequency: FREQUENT
  evidence:
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological findings revealed that most patients had muscle hypotonia, cerebellar ataxia, dystonia, and spastic paralysis."
    explanation: Nationwide cohort documents dystonia as a common neurological finding.
- name: Spasticity
  description: Increased muscle tone contributing to the complex movement disorder of GLUT1DS.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  frequency: FREQUENT
  evidence:
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological findings revealed that most patients had muscle hypotonia, cerebellar ataxia, dystonia, and spastic paralysis."
    explanation: Nationwide cohort documents spastic paralysis as a common neurological finding.
- name: Paroxysmal Exercise/Exertion-Induced Dyskinesia
  description: >-
    Episodic dystonic or dyskinetic attacks of the extremities triggered by
    prolonged physical exertion, hunger, fever, or fatigue; the dominant
    presenting feature of the milder GLUT1DS2/DYT18 phenotype but also reported
    in classic disease.
  phenotype_term:
    preferred_term: Paroxysmal dyskinesia
    term:
      id: HP:0007166
      label: Paroxysmal dyskinesia
    temporality: RECURRENT
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, paroxysmal episodes of ataxia, dystonia/dyskinesia, and motor paralysis were described in approximately 1/3 of all patients. The factors that frequently aggravated these events were hunger, exercise, fever, and fatigue, in that order."
    explanation: Nationwide cohort quantifies paroxysmal dyskinetic episodes in about a third of patients and identifies exertion/hunger/fever/fatigue as triggers.
- name: Speech Difficulty
  description: >-
    Dysarthria and other speech production difficulties associated with the
    movement disorder and developmental impairment of GLUT1DS.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the predominant clinical findings of Glut1DS are usually complex paroxysmal movement disorders, spasticity, ataxia, dystonia, speech difficulty, and intellectual disability."
    explanation: GeneReviews lists speech difficulty among predominant clinical findings in the later-onset presentation.
- name: Hypotonia
  description: Reduced muscle tone, frequently observed alongside ataxia and dystonia.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  frequency: FREQUENT
  evidence:
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological findings revealed that most patients had muscle hypotonia, cerebellar ataxia, dystonia, and spastic paralysis."
    explanation: Nationwide cohort documents muscle hypotonia as a common neurological finding.
genetic:
- name: SLC2A1
  gene_term:
    preferred_term: SLC2A1
    term:
      id: hgnc:11005
      label: SLC2A1
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  frequency: "About 90% de novo; about 10% inherited from a parent"
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Glut1DS is most commonly caused by a heterozygous SLC2A1 pathogenic variant and inherited in an autosomal dominant manner. About 90% of individuals with Glut1DS have the disorder as the result of a de novo SLC2A1 pathogenic variant; about 10% of individuals have the disorder as the result of a pathogenic variant inherited from a parent."
    explanation: GeneReviews genetic counseling section quantifies the de novo versus inherited variant origin split.
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathological mutations in the SLC2A1 gene were identified in 28 out of 32 cases (87.5%)."
    explanation: Nationwide Japanese cohort documents the molecular diagnostic yield of SLC2A1 testing among clinically suspected patients.
biochemical:
- name: Hypoglycorrhachia
  presence: Decreased
  context: >-
    Low CSF glucose relative to blood glucose (CSF:blood glucose ratio typically
    below 0.4) in the setting of normoglycemia is the classic diagnostic
    biochemical signature of GLUT1DS, reflecting impaired GLUT1-mediated glucose
    transport across the blood-brain barrier.
  biomarker_term:
    preferred_term: Hypoglycorrhachia
    term:
      id: HP:0011972
      label: Hypoglycorrhachia
  readouts:
  - target: Reduced GLUT1 Transporter Function at the Blood-Brain Barrier
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      A low CSF:blood glucose ratio reports reduced GLUT1-mediated glucose
      transport across the blood-brain barrier independent of systemic glucose
      levels.
    evidence:
    - reference: PMID:21649651
      reference_title: "Milder phenotypes of glucose transporter type 1 deficiency syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the presence of normoglycaemia with a CSF/blood glucose ratio of less than 0.4."
      explanation: Directly defines the diagnostic CSF:blood glucose ratio cutoff used clinically.
  evidence:
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean CSF/blood glucose ratio was 0.36 (0.28-0.48)."
    explanation: Nationwide cohort of confirmed cases reports the empirical mean and range of the diagnostic CSF:blood glucose ratio.
  - reference: PMID:12029447
    reference_title: "Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain-- a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The hallmark of the disease is a low glucose concentration in the CSF (hypoglycorrhachia) in the presence of normoglycaemia (CSF/blood glucose ratio <0.4)."
    explanation: Review confirms hypoglycorrhachia with CSF:blood glucose ratio below 0.4 as the diagnostic hallmark.
diagnosis:
- name: Lumbar Puncture with Paired CSF and Blood Glucose
  description: >-
    Fasting lumbar puncture with simultaneous blood glucose measurement to
    demonstrate hypoglycorrhachia and calculate the CSF:blood glucose ratio,
    the key diagnostic biochemical test.
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of Glut1DS is established in a proband with suggestive clinical findings, hypoglycorrhachia documented by lumbar puncture, and a (usually) heterozygous pathogenic variant in SLC2A1 identified by molecular genetic testing."
    explanation: GeneReviews establishes lumbar puncture-documented hypoglycorrhachia as a core diagnostic criterion.
- name: SLC2A1 Molecular Genetic Testing
  description: >-
    Sequence analysis (and, if negative, gene-targeted deletion/duplication
    analysis) of SLC2A1 to identify the causative pathogenic variant.
  evidence:
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathological mutations in the SLC2A1 gene were identified in 28 out of 32 cases (87.5%)."
    explanation: Nationwide cohort demonstrates the diagnostic yield of SLC2A1 molecular testing in clinically suspected cases.
- name: Erythrocyte GLUT1 Function Assay
  description: >-
    The GLUT1 defect can be confirmed in erythrocytes by glucose uptake studies
    and GLUT1 immunoreactivity, providing a functional confirmatory test
    alongside molecular genetic testing.
  evidence:
  - reference: PMID:12029447
    reference_title: "Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain-- a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The GLUT1 defect can be confirmed in erythrocytes by glucose uptake studies and GLUT1 immunoreactivity, and by molecular analysis of the GLUT1 gene."
    explanation: Review documents erythrocyte glucose uptake and GLUT1 immunoreactivity as confirmatory functional diagnostic assays.
- name: METAglut1 Erythrocyte Surface GLUT1 Blood Test
  description: >-
    METAglut1 is a simple, noninvasive flow-cytometry blood test that
    quantifies GLUT1 protein on the surface of circulating erythrocytes,
    prospectively validated as a diagnostic test for GLUT1 deficiency syndrome
    and an alternative or complement to lumbar puncture. It can detect patients
    with SLC2A1 mosaicism and variants of unknown significance.
  evidence:
  - reference: PMID:37076312
    reference_title: "Prospective Multicenter Validation of a Simple Blood Test for the Diagnosis of Glut1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "METAglut1 was 80% sensitive and >99% specific for the diagnosis of Glut1DS."
    explanation: Prospective multicenter validation reports the diagnostic sensitivity and specificity of the METAglut1 erythrocyte-surface GLUT1 blood test.
  - reference: PMID:37076312
    reference_title: "Prospective Multicenter Validation of a Simple Blood Test for the Diagnosis of Glut1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "METAglut1 succeeded to identify patients with Glut1DS with SCL2A1 mosaicism and variants of unknown significance."
    explanation: The blood test detects diagnostically challenging cases including SLC2A1 mosaicism and variants of unknown significance.
treatments:
- name: Ketogenic Diet Therapy
  description: >-
    Age-specific ketogenic diet therapies (KDTs) supply ketone bodies as an
    alternative fuel for brain energy metabolism, bypassing the GLUT1 transport
    defect. Earlier initiation, ideally in infancy, is associated with better
    seizure control and long-term neurologic outcome. Effective for both
    seizure control and the movement disorder.
  treatment_term:
    preferred_term: ketogenic diet intake
    term:
      id: NCIT:C173168
      label: Ketogenic Diet
  target_mechanisms:
  - target: Cerebral Glucose Energy Deficit
    treatment_effect: BYPASSES
    evidence:
    - reference: PMID:20301603
      reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Targeted therapy: Age-specific KDTs primarily provide a supplemental fuel, namely, ketone bodies, for brain energy metabolism."
      explanation: GeneReviews describes the ketogenic diet mechanism of action as supplying an alternative cerebral fuel that bypasses the GLUT1 transport defect.
  evidence:
  - reference: PMID:36303089
    reference_title: "Ketogenic diet therapy in children with epilepsy caused by SLC2A1 mutations: a single-center single-arm retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients were seizure-free within a month of receiving the diet therapy. All patients were followed up for six months, three were followed up for 12 months after the treatment, and there was no recurrence of epilepsy during this period."
    explanation: Retrospective single-center cohort of SLC2A1-mutation patients demonstrates rapid and durable seizure control with ketogenic diet therapy.
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Typically, the earlier the treatment the better the long-term clinical outcome."
    explanation: GeneReviews documents that earlier ketogenic diet initiation yields better long-term neurologic outcome.
- name: Triheptanoin
  description: >-
    Triheptanoin is an anaplerotic odd-chain (C7) medium-chain triglyceride
    that provides Krebs-cycle substrates and an alternative brain fuel
    independent of GLUT1. An open-label study reported marked reduction of
    non-epileptic paroxysmal manifestations and normalized brain bioenergetics,
    but a subsequent randomized placebo-controlled trial did not show a
    significant reduction in seizure frequency in patients not on a ketogenic
    diet, leaving its efficacy for the epilepsy phenotype unproven.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Triheptanoin
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Cerebral Glucose Energy Deficit
    treatment_effect: BYPASSES
    evidence:
    - reference: PMID:26536893
      reference_title: "Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Treatment with triheptanoin resulted in a 90% clinical improvement in non-epileptic paroxysmal manifestations and a normalised brain bioenergetics profile in patients with GLUT1-DS."
      explanation: Open-label study demonstrates triheptanoin supplies anaplerotic Krebs-cycle substrates that bypass the GLUT1 defect and normalize brain energy metabolism.
  evidence:
  - reference: PMID:26536893
    reference_title: "Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment with triheptanoin resulted in a 90% clinical improvement in non-epileptic paroxysmal manifestations and a normalised brain bioenergetics profile in patients with GLUT1-DS."
    explanation: Open-label pilot study supports triheptanoin efficacy against the non-epileptic paroxysmal (movement-disorder) manifestations of GLUT1DS.
  - reference: PMID:35441706
    reference_title: "A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Triheptanoin did not significantly reduce seizure frequency in patients with Glut1DS not on the ketogenic diet."
    explanation: Randomized double-blind placebo-controlled trial qualifies the treatment claim by showing no significant seizure-frequency benefit for the epilepsy phenotype.
- name: Anti-Seizure Medications to Avoid
  description: >-
    In individuals on ketogenic diet therapy, valproic acid should be avoided
    because it increases the risk of a Reye-like illness and may also inhibit
    glucose transport; phenobarbital, acetazolamide, topiramate, and zonisamide
    may be relatively contraindicated as adjunctive treatment. This is a
    "circumstance to avoid" (GeneReviews Agents/Circumstances to Avoid section)
    rather than a recommended treatment; retained here as a treatment-adjacent
    drug-safety note.
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Agents/circumstances to avoid: In individuals on KDTs: (1) avoidance of treatment of seizures with valproic acid, because it increases the risk of a Reye-like illness and may also inhibit glucose transport; (2) other anti-seizure medications (ASMs) including phenobarbital, acetazolamide, topiramate, and zonisamide may be relatively contraindicated as adjunctive treatment."
    explanation: GeneReviews Agents/Circumstances to Avoid section directly documents these drug-safety warnings for GLUT1DS patients on ketogenic diet therapy.
- name: Multidisciplinary Supportive Care
  description: >-
    Physical medicine and rehabilitation, physical therapy, occupational
    therapy, speech and language therapy, educational programs, and clinical
    genetics/genetic counseling, alongside routine neurology follow-up to
    monitor response to ketogenic diet therapy and identify new manifestations.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Supportive care: In addition to educational programs to address the individual's needs, multidisciplinary care by specialists in neurology familiar with KDTs, physical medicine and rehabilitation, physical therapy, occupational therapy, speech and therapy, and clinical genetics and genetic counseling."
    explanation: GeneReviews management section documents the multidisciplinary supportive care regimen recommended alongside ketogenic diet therapy.
prevalence:
- population: Estimated (literature-based, likely underascertained)
  measure_type: POINT_PREVALENCE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    No single precise population point-prevalence estimate was identified with
    a directly quotable abstract snippet during this curation pass; the Japan
    nationwide survey below instead gives a national case-ascertainment count
    that is informative but not a normalized rate, and is likely an
    underestimate due to underdiagnosis. This is recorded in notes rather than
    as a fabricated rate_per_100000 value.
  evidence:
  - reference: PMID:25487684
    reference_title: "Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A questionnaire to survey the number of genetically and clinically confirmed cases of GLUT-1DS was sent to 1018 board-certified pediatric neurologists, which resulted in 57 patients being reported."
    explanation: Nationwide Japanese survey ascertained 57 genetically/clinically confirmed cases nationally, informative for rarity but not directly convertible to a per-100,000 rate without further population denominators.
datasets: []
discussions:
- discussion_id: gap_glut1_energy_deficit_to_hyperexcitability_intermediate
  prompt: >-
    Which cellular intermediate translates chronic cerebral glucose
    under-supply into the specific pattern of neuronal hyperexcitability and
    hypersynchrony seen in Glut1DS — failure of the astrocyte-neuron lactate
    shuttle, selective energy vulnerability of fast-spiking GABAergic
    interneurons, disturbed adenosine/thalamocortical signaling, or a
    combination?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Cerebral Glucose Energy Deficit
  - pathophysiology#Neuronal Hyperexcitability and Hypersynchrony
  rationale: >-
    The causal edge from "Cerebral Glucose Energy Deficit" to "Neuronal
    Hyperexcitability and Hypersynchrony" is curated as
    INDIRECT_KNOWN_INTERMEDIATES, but the identity of that intermediate is not
    actually established. Glucose reaches the brain almost exclusively through
    GLUT1, yet why a global fuel shortfall produces the particular Glut1DS
    electroclinical signature (including 2.5-4 Hz generalized spike-wave and
    absence-like seizures) rather than diffuse depression is unresolved.
    Candidate mechanisms — astrocytic lactate-supply failure, preferential ATP
    starvation of parvalbumin interneurons whose high firing rates make them
    metabolically expensive, and adenosine-mediated network effects — carry
    different therapeutic implications, so resolving the intermediate would
    materially sharpen the mechanism model.
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Glucose, the essential metabolic fuel for the brain, is transported into the brain exclusively by the protein glucose transporter type 1 (Glut1) across the endothelial cells forming the blood-brain barrier (BBB)."
    explanation: >-
      Establishes the exclusive GLUT1 route for cerebral glucose, framing why
      the deficit is global; the open question is which cell type first
      converts that global shortfall into focal-onset hyperexcitability.
  - reference: PMID:16497725
    reference_title: "A mouse model for Glut-1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "GLUT-1+/- mice have epileptiform discharges on electroencephalography (EEG), impaired motor activity, incoordination, hypoglycorrhachia, microencephaly, decreased brain glucose uptake as measured by positron emission tomography (PET) scan and decreased brain Glut-1 expression by western blot (66%)."
    explanation: >-
      Provides a tractable in vivo system in which the epileptiform phenotype is
      reproduced, i.e., a model where the missing cellular intermediate could be
      dissected with cell-type-specific readouts.
  proposed_experiments:
  - experiment_id: exp_glut1_celltype_metabolic_intermediate
    name: Cell-type-resolved metabolic-to-excitability mapping in Glut1 haploinsufficiency
    description: >-
      In GLUT-1+/- mice and patient-derived iPSC neuron-astrocyte co-cultures,
      simultaneously measure astrocytic lactate output, interneuron-specific
      ATP/metabolic stress, and network excitability, then test whether
      interneuron-targeted metabolic rescue (or lactate supplementation)
      normalizes hypersynchrony independently of restoring bulk neuronal
      glucose.
    experiment_type:
      preferred_term: cell-type-resolved metabolic and excitability mapping experiment
    perturbations:
    - name: Interneuron-selective metabolic rescue
      target: pathophysiology#Cerebral Glucose Energy Deficit
      description: >-
        Selectively supply alternative fuel (lactate/ketone) or restore GLUT1 in
        astrocytes vs interneurons vs principal neurons to identify the
        rate-limiting compartment.
    readouts:
    - name: Network hyperexcitability
      target: pathophysiology#Neuronal Hyperexcitability and Hypersynchrony
      assays:
      - preferred_term: multielectrode array recording
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Wild-type co-cultures
      description: GLUT1-normal neuron-astrocyte co-cultures under matched glucose conditions.
    decision_criterion: >-
      An intermediate is supported if rescuing a single cell compartment (e.g.,
      astrocytic lactate supply or interneuron energetics) normalizes network
      excitability while leaving bulk neuronal glucose uptake unchanged.
    would_support:
    - pathophysiology#Neuronal Hyperexcitability and Hypersynchrony

- discussion_id: gap_glut1_ketogenic_seizure_vs_neurodevelopment_dissociation
  prompt: >-
    Why does ketone-based fuel substitution robustly control seizures in Glut1DS
    yet only partially rescue the movement disorder and cognitive impairment —
    is the residual deficit a missed developmental window, regional or
    functional under-supply of ketone-derived fuel, or a non-fuel role of
    glucose that ketones cannot replace?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Cerebral Glucose Energy Deficit
  - pathophysiology#Impaired Neurodevelopment and Movement Disorder
  - pathophysiology#Recurrent Pharmacoresistant Seizures
  rationale: >-
    Ketogenic diet therapy is the mainstay treatment and supplies ketone bodies
    as an alternative cerebral fuel that bypasses the GLUT1 transport defect. In
    practice it controls seizures far more completely than it reverses the
    paroxysmal movement disorder, ataxia/dystonia, or cognitive outcome, and
    outcomes are consistently better with earlier treatment. Whether the
    residual, seizure-independent morbidity reflects irreversible injury
    incurred before diagnosis (a developmental-window effect), inadequate
    ketone delivery to specific circuits, or a role of glucose beyond bulk fuel
    (e.g., biosynthetic/pentose-phosphate demands) is unresolved — and it
    determines whether earlier or supplemental (e.g., anaplerotic) therapy could
    close the gap.
  evidence:
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Targeted therapy: Age-specific KDTs primarily provide a supplemental fuel, namely, ketone bodies, for brain energy metabolism."
    explanation: >-
      Establishes that ketogenic therapy acts by fuel substitution, framing the
      question of why fuel substitution rescues seizures more completely than
      neurodevelopmental outcomes.
  - reference: PMID:20301603
    reference_title: "Glucose Transporter Type 1 Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Typically, the earlier the treatment the better the long-term clinical outcome."
    explanation: >-
      Documents the developmental-window dependence of outcome, one of the
      competing explanations for the residual neurodevelopmental deficit.
  - reference: PMID:28106060
    reference_title: "Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Restoring the protein to 2-week old mutants, in which certain disease characteristics are readily apparent, is less effective in shaping normal brain microvasculature."
    explanation: >-
      Model-organism evidence that later restoration incompletely reverses
      structural brain defects, supporting a developmental-window contribution
      to residual, seizure-independent morbidity.
  proposed_experiments:
  - experiment_id: exp_glut1_treatment_timing_endpoint_dissociation
    name: Treatment-timing dissociation of seizure vs neurodevelopmental endpoints
    description: >-
      In GLUT-1+/- mice, initiate ketogenic therapy or GLUT1 repletion across a
      graded set of ages and measure seizure/EEG control separately from motor
      coordination, brain growth, and cognitive-behavioral endpoints, testing
      whether the neurodevelopmental endpoints have an earlier closing window
      than the seizure endpoint.
    experiment_type:
      preferred_term: treatment-timing endpoint dissociation experiment
    perturbations:
    - name: Age-graded ketogenic/repletion therapy
      target: pathophysiology#Cerebral Glucose Energy Deficit
      description: Start fuel substitution or GLUT1 repletion at several developmental ages.
    readouts:
    - name: Seizure control
      target: pathophysiology#Recurrent Pharmacoresistant Seizures
      assays:
      - preferred_term: electroencephalography
      direction: NEGATIVE
    - name: Motor and neurodevelopmental outcome
      target: pathophysiology#Impaired Neurodevelopment and Movement Disorder
      assays:
      - preferred_term: behavioral assay
      direction: POSITIVE
    controls:
    - name: Untreated mutants and wild-type
      description: Matched untreated GLUT-1+/- and wild-type animals.
    decision_criterion: >-
      A developmental-window explanation is supported if neurodevelopmental
      endpoints lose responsiveness at an earlier treatment age than seizure
      control does; a fuel-limitation explanation is supported if both endpoints
      respond equally whenever adequate alternative fuel is supplied.
    would_support:
    - pathophysiology#Impaired Neurodevelopment and Movement Disorder

- discussion_id: gap_glut1_mouse_model_paroxysmal_phenotype_fidelity
  prompt: >-
    Does the GLUT-1+/- mouse faithfully model the full human Glut1DS phenotype —
    in particular the paroxysmal features (paroxysmal eye-head movements,
    exercise-induced dyskinesia) and the spectrum extending to early-onset
    absence epilepsy and movement-disorder-predominant presentations — or does
    it capture mainly the core seizure/hypoglycorrhachia/microcephaly triad?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Neuronal Hyperexcitability and Hypersynchrony
  - pathophysiology#Impaired Neurodevelopment and Movement Disorder
  rationale: >-
    The GLUT-1+/- mouse reproduces epileptiform EEG, motor impairment,
    hypoglycorrhachia and microencephaly and is described as mimicking the
    classical human presentation, making it the workhorse model for Glut1DS.
    But the human disorder is defined as much by paroxysmal, activity- and
    fasting-triggered phenomena and by a wide phenotypic spectrum (paroxysmal
    exercise-induced dyskinesia, early-onset absence epilepsy, isolated
    movement disorder) that depend on human-specific behavioral repertoire and
    developmental glucose-demand timing. Whether these paroxysmal and
    spectrum-defining features are recapitulated — and thus whether the model
    can validate therapies aimed at them — is the open translational question,
    distinct from a claim that evidence is simply absent.
  evidence:
  - reference: PMID:16497725
    reference_title: "A mouse model for Glut-1 haploinsufficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The GLUT-1+/- murine phenotype mimics the classical human presentation of Glut-1 DS."
    explanation: >-
      Documents fidelity to the classical core phenotype; the open question is
      whether the paroxysmal and spectrum-defining human features are also
      captured.
  proposed_experiments:
  - experiment_id: exp_glut1_paroxysmal_phenotype_provocation
    name: Provocation phenotyping of paroxysmal features in Glut1 models
    description: >-
      Deep-phenotype GLUT-1+/- mice and patient-derived neuronal/BBB models
      under physiological provocations (fasting, exertion, post-prandial state)
      to test for movement-triggered dyskinesia-like events and absence-like
      spike-wave, comparing directly against the documented human paroxysmal
      spectrum.
    experiment_type:
      preferred_term: provocation phenotyping experiment
    readouts:
    - name: Paroxysmal movement and absence-like events
      target: pathophysiology#Impaired Neurodevelopment and Movement Disorder
      assays:
      - preferred_term: behavioral assay
      - preferred_term: electroencephalography
      direction: POSITIVE
    controls:
    - name: Wild-type littermates under identical provocation
      description: Matched wild-type animals exposed to the same fasting/exertion protocols.
    decision_criterion: >-
      Human fidelity for the paroxysmal spectrum is supported if physiological
      provocations reproducibly elicit movement-triggered dyskinesia-like events
      and absence-like discharges in mutants but not controls; absence of such
      events flags a genuine human/model mismatch for these features.
    would_support:
    - pathophysiology#Impaired Neurodevelopment and Movement Disorder

📚

References & Deep Research

References

1

PMID:20301603

Glucose Transporter Type 1 Deficiency Syndrome.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

GLUT1 Deficiency Syndrome (GLUT1-DS / De Vivo Disease): Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 40 citations 2026-07-25T19:42:19.039353

GLUT1 Deficiency Syndrome (GLUT1-DS / De Vivo Disease): Comprehensive Research Report

Key Identifiers

System	ID
MONDO	MONDO:0011724 (GLUT1-DS overall); note two OMIM allelic subentries below map to related MONDO terms for classic vs. paroxysmal-dyskinesia phenotype
OMIM	#606777 (GLUT1DS1, classic/severe phenotype); #612126 (GLUT1DS2, paroxysmal exercise-induced dyskinesia phenotype)
Orphanet	ORPHA:71277 (Classic glucose transporter type 1 deficiency syndrome); Orphanet also lists non-classic forms
Gene (HGNC)	SLC2A1, HGNC:11005; chromosome 1p34.2
ICD-10-CM	E74.810 (Glucose transporter protein type 1 deficiency)
MeSH	GLUT1 Deficiency Syndrome (regularly indexed under "Carbohydrate Metabolism, Inborn Errors" and "Glucose Transport Proteins, Facilitative")
GARD (NIH)	22724
Common synonyms	GLUT1DS; De Vivo disease; Glucose transporter type 1 deficiency syndrome; Glucose transporter protein syndrome (GTPS); GLUT1 encephalopathy; Glut-1 deficiency syndrome (early literature also called it "cerebral glucopenia")

1. Disease Information

GLUT1 deficiency syndrome (GLUT1-DS) is a rare, autosomal dominant, treatable neurometabolic ("brain energy failure") disorder caused by impaired facilitative transport of glucose across the blood–brain barrier (BBB), mediated by the GLUT1 transporter encoded by SLC2A1. Because the brain depends almost exclusively on glucose transported by GLUT1 for its energy needs, haploinsufficiency of this transporter produces chronic cerebral energy deficiency (neuroglycopenia) despite normal peripheral blood glucose (Nature Genetics, 1998, PMID:9462754; GeneReviews, NBK1430).

The disease was first clinically described by Darryl De Vivo and colleagues in 1991 in two children with persistent hypoglycorrhachia, seizures, and developmental delay ("Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay," NEJM 1991;325:703–9, PMID:1714544). The molecular basis (heterozygous SLC2A1 mutations) was established by Seidner et al. in 1998 (Nat Genet 18:188–191, PMID:9462754).

Information source type: Most published knowledge derives from aggregated disease-level resources — national/international patient registries (e.g., the Italian GLUT1-DS registry, Orphanet J Rare Dis 2023, PMID pending indexing), multi-center case series, and a formal international consensus statement (Klepper et al. 2020, Epilepsia Open, PMID:32913944, PMC7469861) — supplemented by individual case reports/small pedigrees rather than large-scale primary EHR mining, reflecting its rarity.

2. Etiology

Disease Causal Factors

GLUT1-DS is a monogenic disorder: heterozygous pathogenic variants in SLC2A1 (chromosome 1p34.2) that reduce GLUT1 expression or function are both necessary and sufficient to cause disease. There is no known infectious or purely environmental cause; the disorder is fundamentally mechanistic/genetic — a transporter haploinsufficiency causing chronic cerebral glucopenia.

Genetic Risk Factors

Causal variants: ~90% of cases arise from de novo heterozygous SLC2A1 variants; ~10% are inherited in an autosomal dominant pattern from a mildly/variably affected parent (Wang et al. 2005, Ann Neurol; Klepper 2020 consensus, PMC7469861).
Variant spectrum: missense, nonsense, frameshift, splice-site, small in-frame indels, and (less commonly) whole/partial gene deletions or microdeletions of 1p34.2. Missense variants are enriched among milder (paroxysmal exercise-induced dyskinesia, GLUT1DS2) phenotypes, whereas truncating variants (nonsense, frameshift, splice-site) and larger deletions are enriched among the classic severe encephalopathy phenotype (GLUT1DS1) — consistent with a genotype-severity gradient tied to residual GLUT1 dosage.
Somatic/germline mosaicism: Reported, including a recently described synonymous SLC2A1 variant causing aberrant mosaic splicing and familial epilepsy/paroxysmal exercise-induced dyskinesia (medRxiv 2025, preprint), and low-level parental germline mosaicism explaining apparently "de novo" recurrences in siblings.
Modifier genes: None robustly established; phenotypic variability within families carrying the identical variant (documented in five-generation pedigrees, Eur J Neurol 2024, PMC11235872) implies stochastic/epigenetic or additional genetic modifiers not yet identified.
Sex: No consistent sex bias in occurrence (autosomal locus); some registries note slightly higher ascertainment in females, likely ascertainment bias rather than biological risk difference.

Environmental Risk Factors (symptom triggers, not causal)

GLUT1-DS itself is not environmentally caused, but symptom expression/severity is modulated by catabolic and metabolic stressors that transiently lower cerebral glucose delivery or increase demand: fasting/prolonged inter-meal intervals, physical exertion, febrile illness, extremes of ambient temperature, and sleep deprivation. These do not cause disease but precipitate paroxysmal events (seizures, dyskinesia, confusion) in genetically predisposed individuals.

Protective Factors

Genetic: No protective SLC2A1 alleles are described; rather, the degree of residual transporter function (missense vs. null variants) inversely correlates with severity.
Environmental: Ketosis is the principal "protective" state — dietary induction of ketone bodies (beta-hydroxybutyrate, CHEBI:20067; acetoacetate, CHEBI:15344) supplies the brain with an alternative fuel that bypasses the GLUT1 defect, since monocarboxylate transporters (MCT1/SLC16A1) are unaffected. Early-life initiation of ketogenic therapy is associated with better cognitive outcome (case-report literature, PMC8472230; Norwegian retrospective cohort, PMID:23448551).
Gene-environment interaction: The central G×E interaction in this disease is that a fixed genetic lesion (reduced GLUT1 dosage) interacts with a modifiable environmental/dietary variable (circulating ketone body availability) to determine phenotypic expression — the entire therapeutic rationale for ketogenic diet therapy rests on this interaction. Conversely, environmental catabolic stress (fasting, exercise, fever) interacts with the fixed genetic lesion to precipitate acute symptoms, and methylxanthines (caffeine, theophylline; CHEBI:27732) have been shown in vitro to further inhibit residual GLUT1 activity and are therefore contraindicated ("Methylxanthines Potentiate GLUT1 Haploinsufficiency In Vitro," Pediatr Res, PMID:11331693-class citation).

3. Phenotypes

GLUT1-DS spans a continuous clinical spectrum from a severe infantile epileptic encephalopathy (classic, GLUT1DS1, OMIM #606777, ~90% of diagnosed cases) to milder paroxysmal movement disorders with or without epilepsy and normal-to-borderline cognition (non-classic/GLUT1DS2, OMIM #612126, ~10%) (Klepper 2020 consensus; PMC7469861).

Symptoms, Signs, and Physical Manifestations

Phenotype	Suggested HPO term	Frequency (classic form)	Onset	Course
Infantile-onset seizures (multiple types: absence, myoclonic, atonic, generalized tonic-clonic, infantile spasms)	Seizure (HP:0001250); Infantile spasms (HP:0012469)	~90% in classic form	Typically 1–4 months (median ~6 months); range neonatal to early childhood	Often refractory to standard antiseizure medications; may lessen with age but be replaced by other paroxysmal phenomena
Acquired (postnatal, deceleration of head growth) microcephaly	Postnatal microcephaly (HP:0005484) / Microcephaly (HP:0000252)	Common in classic, less so in mild form	Progressive after normal birth head circumference	Progressive in untreated/late-treated classic cases; stabilizes with early ketogenic treatment
Global developmental delay / intellectual disability	Global developmental delay (HP:0001263); Intellectual disability (HP:0001249)	Nearly universal in classic form; variable (subtle learning difficulty to severe) across spectrum	Infancy–early childhood	Often stabilizes, sometimes improves, with early dietary therapy; may persist as static encephalopathy
Complex movement disorder: ataxia, dystonia, spasticity, chorea	Ataxia (HP:0001251); Dystonia (HP:0001332); Spasticity (HP:0001257); Chorea (HP:0002072)	Common, variable severity	Childhood, often worsens with fatigue/fasting	Fluctuating/paroxysmal component plus a fixed baseline component in many patients
Paroxysmal exercise-induced dyskinesia (PED)	Exercise-induced dyskinesia — closest general term "Dyskinesia" (HP:0100660); a specific "paroxysmal dyskinesia" term should be verified in current HPO before KB use	~80–90% of the "GLUT1DS2" mild phenotype; also seen in adults with classic form	Childhood–adulthood; often the presenting/only feature in mild disease	Episodic, precipitated by exercise, fasting, stress; lifelong
Abnormal eye-head movements (paroxysmal, non-epileptic saccadic eye movements with head nodding)	No single well-established HPO ID identified in this search — recommend verifying via HPO browser/OAK before curation	Reported as one of the earliest infantile signs, often preceding seizures	Infancy (as early as first weeks of life)	Often subsides but is a key early red flag
Migraine / recurrent headache	Migraine (HP:0002076)	~50% of adults	Any age, often increases in adolescence/adulthood	Episodic
Episodic confusion, lethargy, or altered awareness	Confusion (HP:0001289)	Common, especially provoked by fasting/exercise	Any age	Episodic
Fatigue	Fatigue (HP:0012378)	~60% of adults	Adulthood especially	Chronic/episodic
Sleep disturbance	Sleep disturbance (HP:0002360)	Reported subset	Any age	Variable
Autism spectrum features, ADHD, anxiety	Autistic behavior (HP:0000729); Attention deficit hyperactivity disorder (HP:0007018); Anxiety (HP:0000739)	Reported subset, more penetrant in classic form	Childhood	Variable

Laboratory Abnormalities

Hypoglycorrhachia (low CSF glucose with normal contemporaneous blood glucose): the biochemical hallmark. CSF:blood glucose ratio typically <0.6 in the broad GLUT1-DS spectrum and <0.35 in classic/severe presentations (multiple sources above). CSF lactate is characteristically low-normal to low (distinguishing it from mitochondrial disease, where lactate is elevated).
Reduced erythrocyte 3-O-methyl-D-glucose (3-OMG) uptake (35–74% of normal, mean ~50%; cutoff <74% giving ~99% sensitivity/100% specificity in the classic radiotracer assay).
Reduced erythrocyte surface GLUT1 quantified by the newer METAglut1 flow-cytometry blood test (80% sensitivity, >99% specificity vs. genetic/CSF gold standard; Neurology 2023, PMID:37076312).

Age of Onset, Severity, Progression, Frequency

Onset: Classic form — infancy (weeks to months); mild/PED form — childhood to adulthood, sometimes not diagnosed until adolescence or adulthood.
Severity: Highly variable, even within families carrying an identical variant (documented extreme intrafamilial variability, PMC11235872), suggesting incomplete/variable expressivity beyond genotype alone.
Progression: Some features (seizures) may improve with age/treatment; others (movement disorder, cognitive profile) tend to be more stable or slowly evolve; families have reported worsening severity across generations ("anticipation-like" clinical pattern, though not true trinucleotide-repeat anticipation) (Orphanet J Rare Dis 2022, PMC9509642).
Frequency by adult phenotype: PED (~80%), fatigue (~60%), low intelligence (~60%), epilepsy (~50%), migraine (~50%); ~20% of adults have above-average intelligence, underscoring the wide phenotypic range.

Quality of Life

Orphanet-registry data on familial (often milder) cases show that quality of life can be normal to near-normal in many adults and is not strongly correlated with the presence of PED or fatigue per se, but classic-phenotype patients with significant intellectual disability and refractory epilepsy have substantially greater functional impairment and caregiver burden (PMC9509642).

4. Genetic/Molecular Information

Causal Gene

SLC2A1 (Solute Carrier Family 2 Member 1), HGNC:11005, chromosome 1p34.2, encodes GLUT1, the primary facilitative glucose transporter of the blood–brain barrier endothelium and astrocytes.
OMIM gene entry: *SLC2A1, 138140.

Pathogenic Variant Spectrum

Variant types: missense (most common overall, and predominant in mild/PED phenotype), nonsense, frameshift, splice-site, small in-frame insertions/deletions, and larger deletions/microdeletions encompassing part or all of SLC2A1 (associated with more severe phenotypes due to larger dosage loss).
Classification (ACMG/AMP via ClinVar/ClinGen): the great majority of disease-causing SLC2A1 variants are classified Pathogenic/Likely Pathogenic; missense variants of uncertain significance (VUS) are not uncommon given the large allelic series and require functional (e.g., erythrocyte uptake) or segregation data to reclassify.
Mechanism: predominantly haploinsufficiency — heterozygous loss-of-function (via nonsense-mediated decay of truncating transcripts, or loss of transporter function/trafficking for missense alleles) reduces total GLUT1 dosage by ~50%, which is sufficient to cause disease because the BBB and astrocytic glucose flux operate near a physiological ceiling with little functional reserve. Some missense variants may act as dominant-negative by co-oligomerizing with wild-type GLUT1 tetramers, though haploinsufficiency is the dominant accepted mechanism (Nat Genet 1998, PMID:9462754).
Population frequency: SLC2A1 loss-of-function variants are constrained in gnomAD (the gene shows a high pLI / strong depletion of predicted-LoF variants in the general population), consistent with a dominant disease mechanism and against a large healthy carrier reservoir; specific pathogenic alleles are essentially private/family-specific rather than recurrent founder alleles, consistent with a largely de novo mutational origin.
Somatic vs. germline: GLUT1-DS is a germline (constitutional heterozygous) disorder; no somatic/mosaic-tumor association is described, though somatic/mosaic transmission within pedigrees (parental mosaicism) has been documented and can confound recurrence-risk counseling.
Epigenetics: No disease-specific DNA methylation or histone-modification signature has been established for GLUT1-DS to date; this remains an unexplored/gap area (no primary literature identified in this search).
Chromosomal abnormalities: Rare cases are caused by contiguous 1p34.2 microdeletions encompassing SLC2A1 (detectable by chromosomal microarray), rather than a single-nucleotide/indel variant — relevant when panel/exome sequencing is negative but clinical/CSF findings are strongly suggestive.

Modifier Genes

None validated; phenotypic variability in identical-genotype families argues for unidentified genetic or non-genetic modifiers (see Etiology, above).

5. Environmental Information

Toxins/occupational exposures: None established as causal.
Lifestyle/triggers: Fasting/prolonged fasting intervals, strenuous or prolonged physical exercise, febrile illness, sleep deprivation, and possibly hot/cold ambient extremes are well-documented symptom precipitants (not causes) across the literature reviewed above.
Pharmacological environmental modifiers: Methylxanthines (caffeine, theophylline) and, per consensus guidance, certain antiseizure/other medications that impair mitochondrial function or glucose handling (e.g., barbiturates, valproate has mixed guidance) are cautioned against because they may further compromise cerebral energy metabolism in a transporter-limited system.
Infectious agents: Not a cause; however, febrile infectious illness is a common trigger of acute symptom exacerbation (seizures, dyskinesia), and GLUT1-DS is an important misdiagnosis pitfall for bacterial meningitis due to its own hypoglycorrhachia (a recent case report describes GLUT1-DS misdiagnosed as bacterial meningitis, PMC12852347) — underscoring the need to consider GLUT1-DS whenever hypoglycorrhachia is found without evidence of CNS infection.

6. Mechanism / Pathophysiology

Causal Chain

Molecular lesion: Heterozygous SLC2A1 variant → reduced GLUT1 protein dosage/function (haploinsufficiency, ~50% reduction) — GO: facilitative glucose transmembrane transporter activity (GO:0005355); D-glucose transmembrane transport (GO:1904659).
Cellular/tissue consequence: Reduced glucose flux across the two principal GLUT1-expressing barriers — brain capillary endothelial cells forming the blood-brain barrier, and astrocytic endfeet that ensheath the capillaries and constitute the "glial-vascular" glucose relay (Human blood-brain barrier GLUT1 is the main astrocyte transporter, PMID:7615345). Suggested CL terms: brain microvascular endothelial cell (CL:0002585); astrocyte (CL:0000127).
Systemic/organ consequence: Chronic cerebral glucopenia despite normal peripheral (blood) glucose — a state of "hungry brain in a fed body." Reduced brain glucose uptake is demonstrable by FDG-PET in patients and in the Glut1+/- mouse model.
Downstream metabolic consequence: Impaired glycolytic ATP generation in neurons and astrocytes → energy failure in metabolically demanding, high-firing-rate neural circuits (cortex, thalamus, cerebellum) → the clinical triad of epilepsy, movement disorder, and cognitive impairment.
Developmental consequence: Sustained energy deficit during a period of high glucose demand for brain growth (myelination, synaptogenesis) contributes to acquired (postnatal) microcephaly and developmental delay if untreated.
Vascular consequence (a newer, non-neuronal arm): Studies in mouse models show that Glut1 deficiency also produces intrinsic brain microvasculature defects (reduced microvessel density, blood-brain barrier structural abnormality) that are prevented by early (pre-symptomatic) restoration of GLUT1 protein, implicating an endothelial-autonomous developmental role for GLUT1 distinct from its acute transport function (Nature Communications 2017, PMID:28106060; JCI Insight, endothelial-specific requirement for Glut1, insight.jci.org/articles/view/145789).

Cellular Processes and Protein Dysfunction

Protein dysfunction: loss-of-function of a 12-transmembrane-domain facilitative hexose uniporter (UniProt P11166, GLUT1_HUMAN); missense variants can disrupt substrate binding, conformational cycling (outward-open/inward-open transition), or ER trafficking/membrane insertion, producing reduced surface expression rather than (or in addition to) reduced intrinsic transport rate.
Metabolic changes: Whole-body/brain shift toward ketone-body and alternate-fuel utilization is therapeutic, since ketone bodies cross the BBB via monocarboxylate transporters (MCT1/SLC16A1), which are GLUT1-independent — the entire rationale for ketogenic diet and triheptanoin therapy.
Immune involvement: Not a primary feature of pathogenesis; GLUT1-DS is not classically an autoimmune or inflammatory disorder (contrast with autoimmune GLUT1 antibody-mediated conditions in the differential, discussed below).
Tissue injury mechanisms: Chronic neuroglycopenic stress rather than acute necrosis/ischemia; the mouse-model microvascular finding above suggests a component of impaired angiogenesis/vascular maturation during brain development, in addition to purely functional transport insufficiency.
Biochemical abnormality: the core biochemical lesion is reduced facilitative glucose transporter dosage/activity, directly measurable as reduced erythrocyte 3-OMG uptake and reduced CSF glucose relative to blood glucose.

Molecular Profiling / Advanced Technologies

No large-scale human single-cell, spatial transcriptomic, or multi-omics dataset specific to GLUT1-DS brain tissue was identified in this search (human brain biopsy material is essentially unobtainable in this disease); most molecular-mechanism data derive from mouse models (see Model Organisms, below) and from erythrocyte-based functional assays as a peripheral surrogate tissue, since RBCs express abundant GLUT1 and are readily accessible.
FDG-PET imaging in patients demonstrates a distinctive pattern of diffusely reduced cerebral (especially thalamic/mesial temporal and dorsal parieto-occipital cortex) glucose uptake, used both diagnostically and as a research readout of cerebral bioenergetic status.

Suggested GO terms: D-glucose transmembrane transport (GO:1904659); glucose homeostasis (GO:0042593); brain development (GO:0007420); blood-brain barrier maintenance/establishment (GO terms under "establishment of blood-brain barrier," GO:0060856); glycolytic process (GO:0006096); ketone body metabolic process (GO:0046950).

7. Anatomical Structures Affected

Organ Level

Primary organ: Brain (central nervous system) — the entire clinical phenotype is a consequence of cerebral energy failure.
Body systems: Nervous system (primary); no primary involvement of other organ systems is described — peripheral glucose metabolism, liver, muscle, and other GLUT1-expressing peripheral tissues (erythrocytes, placenta, blood-retina barrier, blood-testis barrier) are relatively spared clinically because GLUT1 is not rate-limiting for glucose delivery in those beds, or redundant transporters (GLUT3, GLUT4, etc.) compensate — though the erythrocyte GLUT1 reduction itself is exploited diagnostically (see Diagnostics).
Secondary/complication-level involvement: Musculoskeletal complications of spasticity/dystonia (contractures); psychiatric/behavioral comorbidity (autism spectrum, ADHD, anxiety) as secondary neurodevelopmental consequences.

Tissue and Cell Level

Blood-brain barrier endothelium — brain microvascular endothelial cell (CL:0002585).
Astrocytes, specifically perivascular astrocytic endfeet — astrocyte (CL:0000127); these form the second GLUT1-dependent relay step delivering glucose from endothelium to neurons.
Neurons (cortical, thalamic, cerebellar Purkinje) — indirectly affected via reduced substrate delivery; suggested CL: neuron (CL:0000540), cerebellar Purkinje cell (CL:0000121) given the ataxia phenotype.
Erythrocytes — glucose uptake assay surrogate tissue; CL:0000232 (erythrocyte).

Subcellular Level

Plasma membrane localization/expression of GLUT1 is the site of the primary defect (GO Cellular Component: plasma membrane, GO:0005886; more specifically, integral component of plasma membrane, GO:0005887).
Mitochondrial ATP-generation is indirectly downstream-limited by reduced glycolytic substrate supply, though mitochondria themselves are not structurally primary in this disease (distinguishing it from primary mitochondrial encephalopathies in the differential diagnosis).

Localization / Lateralization

Diffuse, bilateral, symmetric cerebral involvement (no lateralizing anatomical lesion); brain MRI is typically structurally normal or shows nonspecific findings, in contrast to focal-lesion epilepsies. Suggested UBERON terms: brain (UBERON:0000955); cerebral cortex (UBERON:0000956); cerebellum (UBERON:0002037).

8. Temporal Development

Onset

Classic form: typically neonatal-to-infantile onset of paroxysmal eye-head movements (often the earliest sign, sometimes within the first weeks of life), followed by seizure onset at a median of a few months of age (commonly cited range 1–4 months, occasionally later into the first year or two).
Non-classic/mild (PED) form: onset can be delayed to later childhood, adolescence, or even adulthood, sometimes presenting first as isolated exercise-induced dyskinesia without epilepsy.
Onset pattern: typically insidious/subacute for the encephalopathic features (developmental delay, microcephaly), but individual paroxysmal events (seizures, dyskinesia, confusional episodes) are acute/episodic.

Progression

Disease course pattern: Best characterized as a static-to-slowly-progressive encephalopathy with superimposed episodic/paroxysmal exacerbations — i.e., a mixed picture rather than purely progressive or purely episodic.
Rate: Untreated classic disease shows progressive deceleration of head growth and worsening developmental trajectory in infancy/early childhood; with treatment (early ketogenic diet), the trajectory can be stabilized or improved.
Duration: Chronic, lifelong condition — there is no spontaneous resolution of the underlying transporter defect, although the relative prominence of specific symptoms (e.g., seizures vs. movement disorder vs. fatigue) shifts across the lifespan.

Patterns

Remission: Seizures may become easier to control or remit with age and/or ketogenic diet; the diet itself is often maintained through childhood and adolescence and sometimes relaxed/liberalized in later adolescence/adulthood under specialist supervision, occasionally with symptom re-emergence.
Critical periods: Early infancy/early childhood is considered a critical window for intervention — the international consensus and multiple retrospective cohorts support that earlier initiation of ketogenic diet therapy is associated with better long-term cognitive/developmental outcomes, implicating a period of heightened vulnerability of the developing brain to glucopenic injury (case-report literature, PMC8472230; Norwegian cohort, PMID:23448551).

9. Inheritance and Population

Epidemiology

Incidence: estimated 1.65–2.22 per 100,000 live births (Journal of Inherited Metabolic Disease 2025 review, PMC12099281).
Prevalence: estimates vary widely across retrospective cohorts, from roughly 1:24,000 to 1:90,000, reflecting ascertainment differences and almost certainly underestimating true prevalence because of a substantial reservoir of undiagnosed mild/minimal-symptom (PED-only or "GLUT1DS2") cases.

Inheritance Pattern

Autosomal dominant. ~90% of cases are de novo; ~10% are inherited from a parent, who may be mildly/atypically affected or, rarely, essentially unaffected/subclinical, complicating recurrence-risk counseling.
Penetrance: high but clinically variable in expressivity — essentially all carriers of a clearly pathogenic SLC2A1 variant show some phenotype (biochemical if not overtly clinical), so this is best described as highly penetrant with markedly variable expressivity rather than incomplete penetrance per se.
Expressivity: markedly variable — documented extreme intrafamilial phenotypic variability with an identical variant across five generations of one family (Eur J Neurol 2024, PMC11235872), and Orphanet-registry data showing familial cases ranging from severe classic encephalopathy to normal-quality-of-life adults with isolated PED.
Genetic anticipation: Not a classic repeat-expansion anticipation disorder, but multiple pedigree reports describe apparent worsening severity in successive generations within some families — mechanism unclear (possibly ascertainment/reporting bias, possibly true modifier effects).
Germline mosaicism: documented and clinically important — can produce sibling recurrence despite an apparently "de novo" proband variant.
Founder effects: No major population-specific founder SLC2A1 allele has been reported in the literature surveyed; most pathogenic variants are private/family-specific, consistent with a predominantly de novo mutational origin rather than an ancestral founder allele.
Consanguinity: Not a relevant risk factor, since this is a dominant (not recessive) disorder; consanguinity is not specifically implicated.
Carrier frequency: Not applicable in the traditional recessive-carrier sense; population database (gnomAD) constraint metrics indicate strong depletion of predicted loss-of-function SLC2A1 alleles in the general (unaffected) population, consistent with dominant disease liability rather than a tolerated heterozygous carrier state.

Population Demographics

Affected populations: Reported across diverse ancestries with no strong evidence for differential prevalence by ethnicity; a large Chinese cohort has been characterized in detail (PMC11958367), and Italian and other European registries provide the most detailed longitudinal natural-history data.
Geographic distribution: No endemic/regional clustering reported; disease occurs worldwide, limited mainly by diagnostic capacity (CSF glucose/lactate testing, genetic testing availability), which likely explains regional differences in reported prevalence.
Sex ratio: No strong, consistently reported sex skew (autosomal dominant, non-sex-linked locus).
Age distribution: Because the classic form typically presents in infancy and the diagnosis is increasingly made across childhood, adolescence, and adulthood as milder phenotypes are recognized, the age distribution of "living with a diagnosis" spans the entire lifespan — a distinguishing feature versus many other severe infantile epileptic encephalopathies.

10. Diagnostics

Clinical/Laboratory Tests

Lumbar puncture / CSF-blood glucose ratio (paired, fasting ≥4h, simultaneous sampling): CSF glucose typically <60 mg/dL (often much lower) with CSF:blood glucose ratio <0.6 (broad spectrum) or <0.35 (classic phenotype); CSF lactate low-to-normal (distinguishing feature from mitochondrial disorders, which show elevated lactate).
Erythrocyte 3-O-methyl-D-glucose (3-OMG) uptake assay: radiotracer-based functional assay of RBC GLUT1 activity; ~98.6% of genetically confirmed patients show reduced uptake (35–74% of normal, mean ~50%); cutoff <74% gives ~99% sensitivity/100% specificity. Limited by need for specialized radiotracer facilities and rapid sample processing.
METAglut1 blood test: newer flow-cytometry-based quantification of GLUT1 on the erythrocyte surface; validated prospectively in a multicenter study (80% sensitivity, >99% specificity vs. combined genetic/CSF criteria; Neurology 2023, PMID:37076312) — a simple, non-invasive alternative/complement to lumbar puncture, especially useful for wider screening including atypical/adult presentations.
Brain FDG-PET: shows diffusely reduced cerebral glucose metabolism, particularly affecting the thalami/mesial temporal structures and posterior cortex — supportive but not required for diagnosis.
EEG: may show generalized spike-wave discharges (often 2.5–4 Hz), sometimes activated by fasting; interictal EEG can also be normal, especially in milder phenotypes.
Brain MRI: typically normal or nonspecific; used mainly to exclude structural/other causes.

Genetic Testing

First-line: targeted SLC2A1 sequencing or a relevant epilepsy/movement-disorder gene panel; given the clinical/biochemical specificity of hypoglycorrhachia, single-gene testing is often appropriate once the phenotype is recognized.
Broader approaches: whole-exome or whole-genome sequencing are increasingly used as first-tier tests in undifferentiated infantile epilepsy/developmental-delay cohorts and will capture SLC2A1 variants; particularly useful when the classic biochemical clue (CSF sampling) has not yet been obtained or the presentation is atypical.
Chromosomal microarray: indicated when sequencing is negative but clinical suspicion remains high, to detect 1p34.2 microdeletions encompassing SLC2A1.
Not applicable/relevant: mitochondrial DNA testing, repeat-expansion testing, karyotyping/FISH (unless a microdeletion is specifically suspected) are not primary tools for this disorder.

Clinical Criteria and Differential Diagnosis

No single formal DSM/ICD diagnostic-criteria algorithm exists (this is a genetic/metabolic, not psychiatric, disorder); the accepted diagnostic approach is the 2020 international Glut1DS study group consensus (Klepper et al., Epilepsia Open, PMC7469861), integrating clinical phenotype + hypoglycorrhachia + confirmatory functional/genetic testing. Key differential diagnoses to exclude: - Bacterial/viral meningitis or other causes of true hypoglycorrhachia (infectious workup is essential, since GLUT1-DS is a well-documented meningitis mimic/misdiagnosis pitfall, PMC12852347). - Other genetic infantile epileptic encephalopathies (e.g., other channelopathies, mitochondrial disorders — distinguished by normal/low, not elevated, CSF lactate in GLUT1-DS). - Other paroxysmal movement disorders (primary paroxysmal kinesigenic/non-kinesigenic dyskinesias due to PRRT2, PNKD, etc.) — distinguished by the exercise-induced trigger pattern and CSF/erythrocyte glucose findings in GLUT1-DS. - Autoimmune GLUT1-antibody-mediated encephalopathy (a distinct, non-genetic, potentially treatable autoimmune condition with overlapping biochemical/clinical features but a different mechanism — antibody-mediated GLUT1 dysfunction rather than a germline transporter mutation).

Screening

No population-based newborn screening program currently exists for GLUT1-DS (it is not detectable by standard metabolic/enzymatic newborn screening panels, since the defect is a transporter, not an enzyme).
Cascade/family testing: recommended for at-risk relatives once a proband's variant is identified, given the ~10% inherited fraction and variable expressivity (a parent may be minimally symptomatic).
Prenatal/preimplantation genetic testing: feasible once a familial pathogenic variant is known, offered through genetic counseling in familial cases.

11. Outcome/Prognosis

Survival/Mortality

No high-quality population-level mortality/life-expectancy statistics specific to GLUT1-DS were identified in this search; the disease is not generally considered to shorten life expectancy per se, though severe, refractory epilepsy in the classic phenotype carries the background risks associated with chronic epilepsy (e.g., injury, and a small SUDEP-type risk common to refractory epilepsies generally, though not specifically quantified for GLUT1-DS in the literature reviewed).

Morbidity and Function

Classic-phenotype patients often have lifelong intellectual disability, motor impairment (ataxia/spasticity/dystonia), and epilepsy, with resulting functional disability requiring ongoing multidisciplinary support (education, physical/occupational therapy).
Milder/PED-predominant phenotype patients can have normal-to-near-normal cognitive and functional outcomes, with the main morbidity being episodic dyskinesia, fatigue, and migraine impacting daily activities/exercise tolerance.
Quality of life: Orphanet familial-case data indicate that quality of life among affected adults in milder familial forms can be comparable to unaffected relatives and is not strongly predicted merely by the presence of PED or fatigue — suggesting that cognitive/developmental severity (largely set by the degree of infantile/childhood energy deficit and treatment timing) is the dominant driver of long-term QoL rather than the paroxysmal symptoms alone (PMC9509642).

Disease Course / Complications

Complications largely stem from chronic refractory epilepsy (injury risk, medication side effects) and chronic movement disorder (orthopedic complications of spasticity/dystonia, e.g., contractures).
Behavioral/psychiatric comorbidity (autism spectrum disorder, ADHD, anxiety) adds to functional burden in a subset.

Prognostic Factors

Genotype severity (truncating/deletion vs. missense) correlates broadly with phenotype severity.
Age at diagnosis/treatment initiation is the most actionable prognostic factor identified in the literature: earlier initiation of ketogenic diet therapy is repeatedly associated with better developmental/cognitive outcomes across case series and retrospective cohorts.
Prognostic biomarkers: no validated molecular biomarker beyond the diagnostic tests above (CSF glucose ratio, 3-OMG uptake, METAglut1) is established as prognostic for long-term trajectory.

12. Treatment

Pharmacotherapy / Dietary Therapy (mainstay)

Ketogenic diet (classic, medium-chain-triglyceride, or modified Atkins variants): the cornerstone, first-line, disease-modifying therapy. By inducing sustained ketosis (elevated beta-hydroxybutyrate, CHEBI:20067, and acetoacetate, CHEBI:15344), the diet supplies the brain with an alternative fuel independent of GLUT1, via monocarboxylate transporters. Described as "the most important treatment," promoting neurodevelopment via ketone-body-derived brain energy; 79% of patients in aggregated series respond favorably in terms of seizure control, with variable effect on developmental delay/movement disorder (2020 consensus, PMC7469861; 5-year prospective nutritional follow-up, Front Nutr 2023, PMC (frontiersin) full text). Suggested MAXO term: dietary intervention (MAXO:0000088) — a more specific "ketogenic diet therapy" MAXO term, if present in the current release, should be verified via OAK before curation.
Antiseizure medications: used adjunctively for seizure control but are typically insufficient alone (seizures are characteristically drug-resistant); certain agents (e.g., phenobarbital) and methylxanthine-containing preparations are cautioned against due to potential further inhibition of residual GLUT1 activity or unfavorable metabolic interactions.
D,L-3-hydroxybutyrate (exogenous ketone body) supplementation: an emerging oral pharmacotherapy explored as a more titratable ketone source than dietary ketogenesis, crossing the BBB directly to bypass GLUT1 (PMC11739118).
Triheptanoin (UX007, an anaplerotic C7 medium-chain triglyceride): metabolized to heptanoate and C4/C5 ketone bodies, providing anaplerotic TCA-cycle substrates and an alternative brain fuel/gluconeogenic precursor.
An open-label French Phase II study (GLUT-HEP, NCT02014883) reported ~90% clinical improvement in non-epileptic paroxysmal manifestations and normalized brain bioenergetics (MRS) (PMID:26536893; long-term follow-up, PMID:30948626).
However, a subsequent randomized, double-blind, placebo-controlled Ultragenyx Phase II trial (NCT01993186) did not show a significant reduction in seizure frequency in patients not on a ketogenic diet (PMID:35441706), and a further randomized crossover trial specifically for paroxysmal movement disorders also did not demonstrate benefit over placebo — illustrating a genuine, evidence-based controversy about triheptanoin's efficacy despite promising open-label signals.

Advanced/Experimental Therapeutics

Gene therapy (AAV-mediated SLC2A1 replacement): extensively validated preclinically — an AAV9/3 tyrosine-mutant vector expressing SLC2A1 under its endogenous promoter, delivered by cerebroventricular injection, improved CSF glucose and motor function in Glut1-deficient mice (PMID:29624790; PMC5238605); intra-cisterna-magna AAV delivery has also been validated for translational dosing/biodistribution in a pig large-animal model (Gene Therapy 2020). A Phase I/II clinical trial is reported to be underway at Jichi Medical University (Japan), recruiting confirmed GLUT1-DS patients to assess AAV-delivered SLC2A1 restoration of CSF glucose and neurological symptoms — the most advanced gene-therapy translational effort identified for this disease.
Red blood cell exchange transfusion: explored as a novel experimental approach (ClinicalTrials.gov NCT04137692), rationale relating to erythrocyte GLUT1 dynamics, though detailed efficacy data were not surfaced in this search.

Surgical/Interventional, Supportive, Rehabilitative

No disease-specific surgical intervention exists (the defect is a transporter, not a structural lesion); vagus nerve stimulation or epilepsy surgery would not be expected to address the underlying transporter defect and are not standard for this indication.
Supportive/rehabilitative care: physical therapy, occupational therapy, and speech-language therapy for the movement disorder and developmental/communication impairments; nutritional monitoring and supplementation (the ketogenic diet requires structured multivitamin/mineral supplementation and monitoring for growth, lipid profile, and bone health, per the 5-year prospective nutritional-status study).

Treatment Outcomes / Strategy

Response rates: ~79% favorable seizure response to ketogenic diet in aggregated series; developmental/movement-disorder response to dietary therapy is present but "less striking" than the seizure response, per the international consensus.
Side effects: ketogenic diet — growth/nutritional concerns (addressed by long-term prospective monitoring), hyperlipidemia, renal stone risk, gastrointestinal intolerance; triheptanoin — generally gastrointestinal side effects in trials.
Treatment algorithm: early recognition (ideally via CSF glucose ratio and/or METAglut1/3-OMG testing) → prompt initiation of ketogenic diet therapy as the backbone → adjunctive antiseizure medication as needed (avoiding methylxanthine-interacting agents) → consideration of triheptanoin/emerging ketone-ester pharmacotherapy in diet-refractory or diet-intolerant patients → long-term multidisciplinary supportive/rehabilitative care → future potential gene-therapy option pending clinical trial maturation.
Personalized medicine: genotype (missense vs. truncating/deletion) informs prognostic counseling but does not yet directly guide a differentiated treatment algorithm; treatment remains phenotype- (not genotype-) directed at present.

Suggested MAXO terms: dietary intervention (MAXO:0000088); pharmacotherapy-related generic term (verify current MAXO release for a specific "ketogenic diet" or "anaplerotic therapy" term before curation); gene therapy — verify whether a dedicated MAXO gene-therapy term exists in the current release.

13. Prevention

Primary prevention: Not applicable in the traditional sense (this is a de novo/dominant germline genetic disorder, not preventable by risk-factor modification); the closest analog is reproductive genetic counseling and prenatal/preimplantation genetic testing in families with a known pathogenic variant.
Secondary prevention (early detection): The strongest evidence-based "prevention" lever in this disease is early diagnosis and early initiation of ketogenic diet therapy, which is associated with better developmental outcomes — effectively preventing the accumulation of glucopenic neurodevelopmental injury rather than preventing the genetic lesion itself.
Screening: No standard newborn screening exists; cascade genetic testing of relatives of an identified proband, and biochemical screening (CSF ratio, 3-OMG, or METAglut1) in any individual presenting with unexplained hypoglycorrhachia, unexplained infantile epilepsy, or unexplained exercise-induced dyskinesia, functions as the practical secondary-prevention/early-detection strategy.
Tertiary prevention: Ongoing ketogenic diet adherence, trigger avoidance (fasting, excessive exertion without adequate metabolic buffering, avoidance of methylxanthines), and structured multidisciplinary monitoring are aimed at preventing complications (seizure-related injury, nutritional deficiency, orthopedic sequelae of movement disorder) once the disease is established.
Immunization: Not specifically relevant; however, prompt/aggressive management of febrile illness (a common trigger) is a practical preventive measure for symptom exacerbation, and routine immunization is not contraindicated or specifically altered by this diagnosis based on available literature.
Genetic counseling: Central to family planning — given ~10% inherited transmission, variable expressivity (an asymptomatic or minimally symptomatic parent can still transmit the disease), and documented germline mosaicism, formal genetic counseling is recommended for all newly diagnosed families.

14. Other Species / Natural Disease

Taxonomy: No well-established naturally occurring GLUT1-DS-equivalent disease in companion animals or wildlife was identified in this search (unlike some other Mendelian metabolic diseases with recognized veterinary/OMIA counterparts). This should be treated as a knowledge gap rather than confirmed absence — a targeted OMIA search would be the next step for a curator wishing to close this gap.
Orthologous gene: Slc2a1/Glut1 is highly conserved across mammals (mouse, rat, pig) and is the ortholog used in all model-organism work described below; NCBI Gene provides direct ortholog mappings (mouse Slc2a1, Gene ID 20525).
Comparative biology: The BBB-glucose-transport role of GLUT1 is evolutionarily conserved across mammals, which is precisely why mouse and pig models (below) faithfully recapitulate aspects of the human disease — supporting strong evolutionary conservation of the underlying disease mechanism.
Zoonotic potential: Not applicable (a non-infectious, genetic, cell-autonomous transporter disorder).

15. Model Organisms

Mouse Models (the dominant model system for this disease)

Glut1+/− heterozygous knockout mouse (haploinsufficiency model): recapitulates the classic human phenotype closely — microcephaly, impaired motor activity, epileptiform EEG discharges, hypoglycorrhachia, and decreased brain glucose uptake by PET imaging (Hum Mol Genet 2006, PMID:16497725). Glut1−/− homozygous knockouts are embryonic lethal, consistent with GLUT1 being essential and with the human disease mechanism being dosage-sensitive haploinsufficiency rather than complete loss.
Glut1^Rgsc200^ mutant mouse (an independently derived hypomorphic allele): homozygotes are embryonic lethal; phenotypes include decreased CSF glucose, deficits in contextual learning, reduced body size, seizure-like behavior, and abnormal EEG — a second, convergent model supporting the core haploinsufficiency mechanism.
A newer Glut1-deficiency mouse model additionally exhibits abnormal sleep-wake patterns and altered brain glucose kinetics, extending the phenotypic characterization beyond the classic triad and modeling the sleep-disturbance phenotype reported in some human patients (Dis Model Mech 2019, PMC6765196).
Therapeutic/gene-therapy testing in mice: AAV9/3-mediated SLC2A1 gene replacement (endogenous GLUT1 promoter) improved CSF glucose and motor function (PMID:29624790); presymptomatic AAV9-mediated GLUT1 repletion prevented brain microvasculature defects and averted disease onset, revealing a developmental/vascular disease component not appreciated from the acute-transport model alone (Nat Commun 2017, PMID:28106060); an endothelial-cell-specific conditional knockout further demonstrated an early, cell-autonomous endothelial requirement for Glut1 (JCI Insight, insight.jci.org/articles/view/145789). A more recent transgenic-human-GLUT1-locus rescue approach reduces disease burden in the mouse model, supporting dosage-restoration as a viable therapeutic strategy (PMC12496523).

Large Animal Models

Pig model (translational vector-delivery study): intra-cisterna-magna AAV delivery using the GLUT1 promoter recapitulated physiological SLC2A1 expression, used specifically to de-risk dosing/biodistribution for eventual human gene-therapy translation (Gene Therapy 2020) — this is a large-animal proof-of-delivery model rather than a spontaneous/disease model.

Cellular / In Vitro Models

Patient-derived erythrocytes serve as the principal, readily accessible "ex vivo human model," used for the 3-OMG uptake assay and METAglut1 flow cytometry, and for in vitro pharmacology studies (e.g., demonstrating that methylxanthines further inhibit residual GLUT1 activity).
No iPSC-derived brain organoid or endothelial/BBB-on-a-chip model specific to GLUT1-DS was identified in this search — a plausible emerging-technology gap for future modeling of human-specific BBB biology, given that mouse BBB glucose transport, while broadly conserved, may not fully recapitulate human-specific vascular/astrocytic biology (a candidate HUMAN_MODEL_MISMATCH-type consideration for KB curation, given that the vascular-developmental phenotype described in mice has not yet been directly confirmed in human tissue).

Model Limitations

Mouse models robustly recapitulate the core electrophysiological and biochemical phenotype (hypoglycorrhachia, seizures, reduced brain glucose uptake, microcephaly-like reduced brain/body size) but cannot fully model the human cognitive/neurodevelopmental and complex movement-disorder (dystonia/PED) phenotypes, nor the marked intrafamilial phenotypic variability seen in human pedigrees carrying identical genotypes — this variability likely reflects modifier or stochastic factors not captured in inbred mouse lines.

Resources

Standard model-organism repositories (MGI for the mouse Slc2a1 alleles; IMSR for strain sourcing) apply; no Drosophila, C. elegans, or zebrafish GLUT1-DS-specific disease model was identified in this search, likely reflecting the mammalian-specific architecture of the blood-brain barrier that GLUT1-DS mechanistically depends on.

Summary Table: Suggested Ontology Terms for KB Curation

Category	Term	ID	Note
Disease	GLUT1 deficiency syndrome	MONDO:0011724	As specified; verify current MONDO release maps correctly to both OMIM #606777/#612126
Gene	SLC2A1	HGNC:11005	Chromosome 1p34.2
Phenotype	Seizure	HP:0001250
Phenotype	Infantile spasms	HP:0012469
Phenotype	Postnatal microcephaly	HP:0005484
Phenotype	Global developmental delay	HP:0001263
Phenotype	Intellectual disability	HP:0001249
Phenotype	Ataxia	HP:0001251
Phenotype	Dystonia	HP:0001332
Phenotype	Spasticity	HP:0001257
Phenotype	Migraine	HP:0002076
Phenotype	Fatigue	HP:0012378
Phenotype	Dyskinesia (nearest general term for PED)	HP:0100660	Verify whether a more specific "paroxysmal exercise-induced dyskinesia" HPO term exists in the current release before use
Cell type	Brain microvascular endothelial cell	CL:0002585	Primary affected cell (BBB)
Cell type	Astrocyte	CL:0000127	Second GLUT1-expressing relay cell
Cell type	Erythrocyte	CL:0000232	Diagnostic surrogate tissue
Biological process	D-glucose transmembrane transport	GO:1904659	Core molecular lesion
Biological process	Brain development	GO:0007420
Biological process	Ketone body metabolic process	GO:0046950	Basis of dietary therapy
Anatomical structure	Brain	UBERON:0000955
Anatomical structure	Cerebral cortex	UBERON:0000956
Chemical	D-3-hydroxybutyrate	CHEBI:20067	Ketone body / therapeutic ketosis
Chemical	Caffeine	CHEBI:27732	Contraindicated methylxanthine
Treatment	Dietary intervention (ketogenic diet)	MAXO:0000088	Verify if a more specific ketogenic-diet MAXO term exists

Note on evidence gaps: Several precise ontology-term IDs above (the PED-specific HPO term, a dedicated ketogenic-diet MAXO term, and any GLUT1-DS-specific GO "establishment of blood-brain barrier" child term) should be independently verified with OAK (runoak -i sqlite:obo:hp/maxo/go info <ID>) before insertion into a curated knowledge base entry, consistent with standard anti-hallucination practice for ontology binding.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Prevalence

Source YAML

References & Deep Research

References

Deep Research

GLUT1 Deficiency Syndrome (GLUT1-DS / De Vivo Disease): Comprehensive Research Report

Key Identifiers

1. Disease Information

2. Etiology

Disease Causal Factors

Genetic Risk Factors

Environmental Risk Factors (symptom triggers, not causal)

Protective Factors

3. Phenotypes

Symptoms, Signs, and Physical Manifestations

Laboratory Abnormalities

Age of Onset, Severity, Progression, Frequency

Quality of Life

4. Genetic/Molecular Information

Causal Gene

Pathogenic Variant Spectrum

Modifier Genes

5. Environmental Information

6. Mechanism / Pathophysiology

Causal Chain

Cellular Processes and Protein Dysfunction

Molecular Profiling / Advanced Technologies

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

Subcellular Level

Localization / Lateralization

8. Temporal Development

Onset

Progression

Patterns

9. Inheritance and Population

Epidemiology

Inheritance Pattern

Population Demographics

10. Diagnostics

Clinical/Laboratory Tests

Genetic Testing

Clinical Criteria and Differential Diagnosis

Screening

11. Outcome/Prognosis

Survival/Mortality

Morbidity and Function

Disease Course / Complications

Prognostic Factors

12. Treatment

Pharmacotherapy / Dietary Therapy (mainstay)

Advanced/Experimental Therapeutics

Surgical/Interventional, Supportive, Rehabilitative

Treatment Outcomes / Strategy

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Mouse Models (the dominant model system for this disease)

Large Animal Models

Cellular / In Vitro Models

Model Limitations

Resources

Summary Table: Suggested Ontology Terms for KB Curation

Sources